<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74681</article-id><article-id pub-id-type="doi">10.7554/eLife.74681</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-256855"><name><surname>Silverstein</surname><given-names>Noah J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5688-9978</contrib-id><email>noah.silverstein@umassmed.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-256856"><name><surname>Wang</surname><given-names>Yetao</given-names></name><email>yetao.wang@umassmed.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256857"><name><surname>Manickas-Hill</surname><given-names>Zachary</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256858"><name><surname>Carbone</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256859"><name><surname>Dauphin</surname><given-names>Ann</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270708"><name><surname>Boribong</surname><given-names>Brittany P</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256861"><name><surname>Loiselle</surname><given-names>Maggie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1051-2072</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256862"><name><surname>Davis</surname><given-names>Jameson</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256863"><name><surname>Leonard</surname><given-names>Maureen M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256864"><name><surname>Kuri-Cervantes</surname><given-names>Leticia</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>MGH COVID-19 Collection &amp; Processing Team<contrib-group><contrib><name><surname>Lavin-Parsons</surname><given-names>Kendall</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Parry</surname><given-names>Blair</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lilley</surname><given-names>Brendan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lodenstein</surname><given-names>Carl</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>McKaig</surname><given-names>Brenna</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Charland</surname><given-names>Nicole</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Khanna</surname><given-names>Hargun</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Margolin</surname><given-names>Justin</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Department of Emergency Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Gonye</surname><given-names>Anna</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Gushterova</surname><given-names>Irena</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lasalle</surname><given-names>Tom</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sharma</surname><given-names>Nihaarika</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Russo</surname><given-names>Brian C</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Rojas-Lopez</surname><given-names>Maricarmen</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sade-Feldman</surname><given-names>Moshe</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Center for Immunology and Inflammatory Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Manakongtreecheep</surname><given-names>Kasidet</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Center for Immunology and Inflammatory Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Tantivit</surname><given-names>Jessica</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Center for Immunology and Inflammatory Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Fisher Thomas</surname><given-names>Molly</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital Center for Immunology and Inflammatory Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Abayneh</surname><given-names>Betelihem A</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Allen</surname><given-names>Patrick</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Antille</surname><given-names>Diane</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Armstrong</surname><given-names>Katrina</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Boyce</surname><given-names>Siobhan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Braley</surname><given-names>Joan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Branch</surname><given-names>Karen</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Broderick</surname><given-names>Katherine</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Carney</surname><given-names>Julia</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Chan</surname><given-names>Andrew</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Davidson</surname><given-names>Susan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Dougan</surname><given-names>Michael</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Drew</surname><given-names>David</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Elliman</surname><given-names>Ashley</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Flaherty</surname><given-names>Keith</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Flannery</surname><given-names>Jeanne</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Forde</surname><given-names>Pamela</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Gettings</surname><given-names>Elise</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Griffin</surname><given-names>Amanda</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Grimmel</surname><given-names>Sheila</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Grinke</surname><given-names>Kathleen</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Hall</surname><given-names>Kathryn</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Healy</surname><given-names>Meg</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Henault</surname><given-names>Deborah</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Holland</surname><given-names>Grace</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Kayitesi</surname><given-names>Chantal</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>LaValle</surname><given-names>Vlasta</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lu</surname><given-names>Yuting</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Luthern</surname><given-names>Sarah</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Marchewka</surname><given-names>Jordan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Martino</surname><given-names>Brittani</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>McNamara</surname><given-names>Roseann</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Nambu</surname><given-names>Christian</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Nelson</surname><given-names>Susan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Noone</surname><given-names>Marjorie</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Ommerborn</surname><given-names>Christine</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Chris Pacheco</surname><given-names>Lois</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Phan</surname><given-names>Nicole</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Porto</surname><given-names>Falisha A</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Ryan</surname><given-names>Edward</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Selleck</surname><given-names>Kathleen</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Slaughenhaupt</surname><given-names>Sue</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sheppard</surname><given-names>Kimberly Smith</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Suschana</surname><given-names>Elizabeth</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Wilson</surname><given-names>Vivine</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Alter</surname><given-names>Galit</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Balazs</surname><given-names>Alejandro</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Bals</surname><given-names>Julia</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Barbash</surname><given-names>Max</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Bartsch</surname><given-names>Yannic</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Boucau</surname><given-names>Julie</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Chevalier</surname><given-names>Josh</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Chowdhury</surname><given-names>Fatema</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Einkauf</surname><given-names>Kevin</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Fallon</surname><given-names>Jon</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Fedirko</surname><given-names>Liz</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Finn</surname><given-names>Kelsey</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Garcia-Broncano</surname><given-names>Pilar</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Hartana</surname><given-names>Ciputra</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Jiang</surname><given-names>Chenyang</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Kaplonek</surname><given-names>Paulina</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Karpell</surname><given-names>Marshall</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lam</surname><given-names>Evan C</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lefteri</surname><given-names>Kristina</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lian</surname><given-names>Xiaodong</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lichterfeld</surname><given-names>Mathias</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Lingwood</surname><given-names>Daniel</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Liu</surname><given-names>Hang</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Liu</surname><given-names>Jinqing</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Ly</surname><given-names>Natasha</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Michell</surname><given-names>Ashlin</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Millstrom</surname><given-names>Ilan</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Miranda</surname><given-names>Noah</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>O’Callaghan</surname><given-names>Claire</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Osborn</surname><given-names>Matthew</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Pillai</surname><given-names>Shiv</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Rassadkina</surname><given-names>Yelizaveta</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Reissis</surname><given-names>Alexandra</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Ruzicka</surname><given-names>Francis</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Seiger</surname><given-names>Kyra</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sessa</surname><given-names>Libera</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sharr</surname><given-names>Christianne</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Shin</surname><given-names>Sally</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Singh</surname><given-names>Nishant</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sun</surname><given-names>Weiwei</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sun</surname><given-names>Xiaoming</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Ticheli</surname><given-names>Hannah</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Trocha-Piechocka</surname><given-names>Alicja</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Worrall</surname><given-names>Daniel</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Zhu</surname><given-names>Alex</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Daley</surname><given-names>George</given-names></name><aff><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Golan</surname><given-names>David</given-names></name><aff><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Heller</surname><given-names>Howard</given-names></name><aff><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Sharpe</surname><given-names>Arlene</given-names></name><aff><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Jilg</surname><given-names>Nikolaus</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Brigham and Women’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Rosenthal</surname><given-names>Alex</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Brigham and Women’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Wong</surname><given-names>Colline</given-names></name><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Brigham and Women’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></collab><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256865"><name><surname>Meyer</surname><given-names>Nuala J</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221355"><name><surname>Betts</surname><given-names>Michael R</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52168"><name><surname>Li</surname><given-names>Jonathan Z</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37115"><name><surname>Walker</surname><given-names>Bruce D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256866"><name><surname>Yu</surname><given-names>Xu G</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256867"><name><surname>Yonker</surname><given-names>Lael M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-55312"><name><surname>Luban</surname><given-names>Jeremy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5650-4054</contrib-id><email>jeremy.luban@umassmed.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Program in Molecular Medicine, University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Medical Scientist Training Program, University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Massachusetts Consortium on Pathogen Readiness</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital, Mucosal Immunology and Biology Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital, Department of Pediatrics</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Institute for Immunology, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Department of Medicine, Brigham and Women’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap><addr-line><named-content content-type="city">Chevy Chase</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a0ya142</institution-id><institution>Broad Institute of Harvard and MIT</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Giamarellos-Bourboulis</surname><given-names>Evangelos J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gnjpq42</institution-id><institution>National and Kapodistrian University of Athens, Medical School</institution></institution-wrap><country>Greece</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028qa3n13</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>11</day><month>03</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74681</elocation-id><history><date date-type="received" iso-8601-date="2021-10-14"><day>14</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-03-11"><day>11</day><month>03</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-01-15"><day>15</day><month>01</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.01.14.21249839"/></event></pub-history><permissions><copyright-statement>© 2022, Silverstein et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Silverstein et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74681-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74681-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Risk of severe COVID-19 increases with age, is greater in males, and is associated with lymphopenia, but not with higher burden of SARS-CoV-2. It is unknown whether effects of age and sex on abundance of specific lymphoid subsets explain these correlations.</p></sec><sec id="abs2"><title>Methods:</title><p>Multiple regression was used to determine the relationship between abundance of specific blood lymphoid cell types, age, sex, requirement for hospitalization, duration of hospitalization, and elevation of blood markers of systemic inflammation, in adults hospitalized for severe COVID-19 (n = 40), treated for COVID-19 as outpatients (n = 51), and in uninfected controls (n = 86), as well as in children with COVID-19 (n = 19), recovering from COVID-19 (n = 14), MIS-C (n = 11), recovering from MIS-C (n = 7), and pediatric controls (n = 17).</p></sec><sec id="abs3"><title>Results:</title><p>This observational study found that the abundance of innate lymphoid cells (ILCs) decreases more than 7-fold over the human lifespan – T cell subsets decrease less than 2-fold – and is lower in males than in females. After accounting for effects of age and sex, ILCs, but not T cells, were lower in adults hospitalized with COVID-19, independent of lymphopenia. Among SARS-CoV-2-infected adults, the abundance of ILCs, but not of T cells, correlated inversely with odds and duration of hospitalization, and with severity of inflammation. ILCs were also uniquely decreased in pediatric COVID-19 and the numbers of these cells did not recover during follow-up. In contrast, children with MIS-C had depletion of both ILCs and T cells, and both cell types increased during follow-up. In both pediatric COVID-19 and MIS-C, ILC abundance correlated inversely with inflammation. Blood ILC mRNA and phenotype tracked closely with ILCs from lung. Importantly, blood ILCs produced amphiregulin, a protein implicated in disease tolerance and tissue homeostasis. Among controls, the percentage of ILCs that produced amphiregulin was higher in females than in males, and people hospitalized with COVID-19 had a lower percentage of ILCs that produced amphiregulin than did controls.</p></sec><sec id="abs4"><title>Conclusions:</title><p>These results suggest that, by promoting disease tolerance, homeostatic ILCs decrease morbidity and mortality associated with SARS-CoV-2 infection, and that lower ILC abundance contributes to increased COVID-19 severity with age and in males.</p></sec><sec id="abs5"><title>Funding:</title><p>This work was supported in part by the Massachusetts Consortium for Pathogen Readiness and NIH grants R37AI147868, R01AI148784, F30HD100110, 5K08HL143183.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>MIS-C</kwd><kwd>innate lymphoid cells</kwd><kwd>disease tolerance</kwd><kwd>amphiregulin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R37AI147868</award-id><principal-award-recipient><name><surname>Luban</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI148784</award-id><principal-award-recipient><name><surname>Luban</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F30HD100110</award-id><principal-award-recipient><name><surname>Silverstein</surname><given-names>Noah J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5K08HL143183</award-id><principal-award-recipient><name><surname>Yonker</surname><given-names>Lael M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Massachusetts Consortium for Pathogen Readiness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Luban</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Homeostatic innate lymphoid cell abundance, adjusted for age and sex, correlates inversely with COVID-19 severity in adults and children.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The outcome of SARS-CoV-2 infection is highly variable with only a minority progressing to severe COVID-19, characterized by acute respiratory distress syndrome, multi-organ dysfunction, elevated inflammatory cytokines, lymphopenia, and other abnormalities of the immune system (<xref ref-type="bibr" rid="bib12">Bonnet et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Giamarellos-Bourboulis et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Huang and Pranata, 2020</xref>; <xref ref-type="bibr" rid="bib48">Kaneko et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Kuri-Cervantes et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Lucas et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Mathew et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Mudd et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Zhou et al., 2020</xref>). The risk of severe COVID-19 and death in people infected with SARS-CoV-2 increases with age and is greater in men than in women (<xref ref-type="bibr" rid="bib2">Alkhouli et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Bunders and Altfeld, 2020</xref>; <xref ref-type="bibr" rid="bib39">Gupta et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Laxminarayan et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Mauvais-Jarvis, 2020</xref>; <xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Peckham et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib95">Scully et al., 2020</xref>). These trends have been observed in people infected with SARS-CoV (<xref ref-type="bibr" rid="bib21">Chen and Subbarao, 2007</xref>; <xref ref-type="bibr" rid="bib29">Donnelly et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Karlberg et al., 2004</xref>), or with MERS-CoV (<xref ref-type="bibr" rid="bib1">Alghamdi et al., 2014</xref>), and in laboratory animals challenged with SARS-CoV or SARS-CoV-2 (<xref ref-type="bibr" rid="bib20">Channappanavar et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Leist et al., 2020</xref>). The mechanisms underlying these effects of age and sex on COVID-19 morbidity and mortality remain poorly understood.</p><p>The composition and function of the human immune system changes with age and exhibits sexual dimorphism (<xref ref-type="bibr" rid="bib26">Darboe et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Klein and Flanagan, 2016</xref>; <xref ref-type="bibr" rid="bib71">Márquez et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Patin et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Solana et al., 2012</xref>), with consequences for survival of infection, response to vaccination, and susceptibility to autoimmune disease (<xref ref-type="bibr" rid="bib33">Flanagan et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Giefing-Kröll et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Márquez et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Mauvais-Jarvis, 2020</xref>; <xref ref-type="bibr" rid="bib80">Patin et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Piasecka et al., 2018</xref>). Better understanding of these effects might provide clues as to why the clinical outcome of SARS-CoV-2 infection is so variable, ranging from asymptomatic to lethal (<xref ref-type="bibr" rid="bib19">Cevik et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Jones et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Lennon et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Ra et al., 2021</xref>; <xref ref-type="bibr" rid="bib90">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Yang et al., 2021</xref>).</p><p>Survival after infection with a pathogenic virus such as SARS-CoV-2 requires not only that the immune system control and eliminate the pathogen, but that disease tolerance mechanisms limit tissue damage caused by the pathogen or by host inflammatory responses (<xref ref-type="bibr" rid="bib7">Ayres, 2020a</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib75">Medzhitov et al., 2012</xref>; <xref ref-type="bibr" rid="bib94">Schneider and Ayres, 2008</xref>). Research with animal models has demonstrated that genetic and environmental factors can promote host fitness without directly inhibiting pathogen replication (<xref ref-type="bibr" rid="bib7">Ayres, 2020a</xref>; <xref ref-type="bibr" rid="bib25">Cumnock et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Jhaveri et al., 2007</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib75">Medzhitov et al., 2012</xref>; <xref ref-type="bibr" rid="bib87">Råberg et al., 2007</xref>; <xref ref-type="bibr" rid="bib92">Sanchez et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Schneider and Ayres, 2008</xref>; <xref ref-type="bibr" rid="bib100">Wang et al., 2016</xref>). Although in most cases the underlying mechanism is unknown, some of these models suggest that subsets of innate lymphoid cells (ILCs) contribute to disease tolerance (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Califano et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>). Some ILC subsets produce the epidermal growth factor family member amphiregulin (AREG) that maintains the integrity of epithelial barriers in the lung and intestine (<xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Jamieson et al., 2013</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), and promotes tissue repair (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib23">Cherrier et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Klose and Artis, 2016</xref>; <xref ref-type="bibr" rid="bib88">Rak et al., 2016</xref>). In models of influenza infection in mice, homeostatic ILCs and exogenous AREG promote lung epithelial integrity, decrease disease severity, and increase survival, without decreasing pathogen burden (<xref ref-type="bibr" rid="bib17">Califano et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Jamieson et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>).</p><p>Little is known about disease tolerance in the context of human infectious diseases. Interestingly, SARS-CoV-2 viral load does not reliably discriminate symptomatic from asymptomatic infection (<xref ref-type="bibr" rid="bib19">Cevik et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Jones et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Lennon et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Ra et al., 2021</xref>; <xref ref-type="bibr" rid="bib107">Yang et al., 2021</xref>). This discrepancy between SARS-CoV-2 viral load and the severity of COVID-19 is especially pronounced in children, who rarely have severe COVID-19 (<xref ref-type="bibr" rid="bib9">Bailey et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Lu et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Poline et al., 2020</xref>), although viral load may be comparable to that in adults with severe COVID-19 (<xref ref-type="bibr" rid="bib42">Heald-Sargent et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">LoTempio et al., 2021</xref>; <xref ref-type="bibr" rid="bib108">Yonker et al., 2020</xref>). These observations suggest that age-dependent, disease tolerance mechanisms influence the severity of COVID-19. In mice, homeostatic ILCs decrease in abundance in the lung with increasing age, and lose their ability to maintain disease tolerance during influenza infection (<xref ref-type="bibr" rid="bib30">D’Souza et al., 2019</xref>). Although the distribution of ILCs within human tissues differs from mice and is heterogeneous among individuals (<xref ref-type="bibr" rid="bib111">Yudanin et al., 2019</xref>), human ILCs share many features with those in mice (<xref ref-type="bibr" rid="bib99">Vivier et al., 2018</xref>) and therefore may perform similar roles in maintaining tissue homeostasis and disease tolerance.</p><p>ILCs in peripheral blood have been reported to be depleted in individuals with severe COVID-19 (<xref ref-type="bibr" rid="bib35">García et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Kuri-Cervantes et al., 2020</xref>), but it is difficult to determine the extent to which ILCs are decreased independently from the overall lymphopenia associated with COVID-19 (<xref ref-type="bibr" rid="bib22">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Huang and Pranata, 2020</xref>; <xref ref-type="bibr" rid="bib113">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib114">Zhao et al., 2020</xref>), or from changes in other blood cell lineages (<xref ref-type="bibr" rid="bib36">Giamarellos-Bourboulis et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Kuri-Cervantes et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Lucas et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Mathew et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Mudd et al., 2020</xref>; <xref ref-type="bibr" rid="bib115">Zheng et al., 2020</xref>). In addition, assessment of lymphoid cell abundance, in the context of a disease for which age and sex are risk factors for severity, is confounded by programmed differences in lymphocyte abundance with age and sex (<xref ref-type="bibr" rid="bib71">Márquez et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Patin et al., 2018</xref>). The goal of this study was to determine whether the abundance of any blood lymphoid cell population was altered in COVID-19, independent of age, sex, and global lymphopenia, and whether abundance of any lymphoid cell population correlated with clinical outcome in SARS-CoV-2 infection.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human BDCA1 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 354,208</td><td align="left" valign="bottom">Clone: 201 A (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD117 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 313,206</td><td align="left" valign="bottom">Clone: 104D2 (APC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD11c (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 301,604</td><td align="left" valign="bottom">Clone: 3.9 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD123 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 306,014</td><td align="left" valign="bottom">Clone: 6H6 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD127 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 351,320</td><td align="left" valign="bottom">Clone: A019D5 (PE/Cyanine7) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD14 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 325,604</td><td align="left" valign="bottom">Clone: HCD14 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD16 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 980,104</td><td align="left" valign="bottom">Clone: 3G8 (APC) (1:400 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD19 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 302,206</td><td align="left" valign="bottom">Clone: HIB19 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD1a (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 300,104</td><td align="left" valign="bottom">Clone: HI149 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD20 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 302,304</td><td align="left" valign="bottom">Clone: 2H7a (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD22 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 363,508</td><td align="left" valign="bottom">Clone: S-HCL-1 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD3 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 317,306</td><td align="left" valign="bottom">Clone: OKT3 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD34 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 343,504</td><td align="left" valign="bottom">Clone: 581 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD4 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 317,428</td><td align="left" valign="bottom">Clone: OKT4 (PerCP/Cyanine5.5) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD4 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 317,408</td><td align="left" valign="bottom">Clone: OKT4 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD45 (mouse monoclonal)</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">Cat# 560,178</td><td align="left" valign="bottom">Clone: 2D1 (APC/H7) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD56 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 318,306</td><td align="left" valign="bottom">Clone: HCD56 (PE) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CD8 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 300,924</td><td align="left" valign="bottom">Clone: HIT8a (PerCP/Cyanine 5.5) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human CRTH2 (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 350,116</td><td align="left" valign="bottom">Clone: BM16 (PerCP/Cyanine5.5) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human FcεR1α (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 334,608</td><td align="left" valign="bottom">Clone: AER-37 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human TBX21 (mouse monoclonal)</td><td align="left" valign="bottom">ebioscience</td><td align="left" valign="bottom">Cat# 25-5825-82</td><td align="left" valign="bottom">Clone: ebio4B10 (PE/Cyanine7) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human TCRα/β (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 306,706</td><td align="left" valign="bottom">Clone: IP26 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human TCRγ/δ (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 331,208</td><td align="left" valign="bottom">Clone: B1 (FITC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human TCF7 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 37,636 s</td><td align="left" valign="bottom">Clone: C63D9 (APC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human IL-13 (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 501,908</td><td align="left" valign="bottom">Clone: JES10-5A2 (APC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Human AREG (mouse monoclonal)</td><td align="left" valign="bottom">ebioscience</td><td align="left" valign="bottom">Cat# 17-5370-42</td><td align="left" valign="bottom">Clone: AREG559</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse IgG1, k isotype control (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 400,112</td><td align="left" valign="bottom">Clone: MOPC-21 (PE) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse IgG1, k isotype control (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 400,120</td><td align="left" valign="bottom">Clone: MOPC-21 (APC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit IgG, isotype control (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 3,452 S</td><td align="left" valign="bottom">(Alexa Fluor 647) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat IgG1, k isotype control (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 400,412</td><td align="left" valign="bottom">Clone: RTK2071 (APC) (1:200 dilution)</td></tr><tr><td align="left" valign="bottom">Biological Samples (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs</td><td align="left" valign="bottom">New York Biologics</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.newyorkbiologics.com/">https://www.newyorkbiologics.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological Samples (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs</td><td align="left" valign="bottom">MassCPR</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://masscpr.hms.harvard.edu/">https://masscpr.hms.harvard.edu/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological Samples (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">PBMCs</td><td align="left" valign="bottom">MGH Pediatric COVID-19 Biorepository</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cell stimulation cocktail</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 00-4970-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protein transport inhibitor</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 00-4980-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TRIzol reagent</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 15596018</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AMPure XP beads</td><td align="left" valign="bottom">Beckman Culter</td><td align="left" valign="bottom">Cat# A63880</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ExoSAP-IT</td><td align="left" valign="bottom">Affymetrix</td><td align="left" valign="bottom">Cat# 78,200</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Live and Dead violet viability kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# L-34963</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Foxp3 /Transcription Factor Staining Buffer Set</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 00-5523-00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">HiScribe T7 High Yield RNA Synthesis Kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E2040S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra II Non directional Second Strand Synthesis Module</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E6111L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R computer software environment (version 4.0.2)</td><td align="left" valign="bottom">The R Foundation <xref ref-type="bibr" rid="bib85">R Development Core Team, 2020</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">FlowJo, LLC</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">tidyverse v1.3.1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib104">Wickham et al., 2019</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.tidyverse.org">https://www.tidyverse.org</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggplot2 v3.3.3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib103">Wickham, 2016</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://ggplot2.tidyverse.org">https://ggplot2.tidyverse.org</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggpubr v0.4.0</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib50">Kassambara, 2020</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://rpkgs.datanovia.com/ggpubr/">https://rpkgs.datanovia.com/ggpubr/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ComplexHeatmap v2.4.3</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib38">Gu et al., 2016</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/jokergoo/ComplexHeatmap">https://github.com/jokergoo/ComplexHeatmap</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">emmeans v1.6.0</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib105">Wieduwilt et al., 2020</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=emmeans">https://CRAN.R-project.org/package=emmeans</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">lme4 v1.1–27</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Bates et al., 2015</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/lme4/index.html">https://cran.r-project.org/web/packages/lme4/index.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">lmerTest v3.1–3</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Kuznetsova et al., 2017</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/lmerTest/index.html">https://cran.r-project.org/web/packages/lmerTest/index.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DolphinNext RNA-Seq pipeline (Revision 4)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib112">Yukselen et al., 2020</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/UMMS-Biocore/dolphinnext">https://github.com/UMMS-Biocore/dolphinnext</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR v2.1.6</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib28">Dobin et al., 2013</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RSEM v1.3.1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib62">Li and Dewey, 2011</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://deweylab.github.io/RSEM/">http://deweylab.github.io/RSEM/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2 v1.28.1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib67">Love et al., 2014</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">clusterProfiler v3.16.1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib110">Yu et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://guangchuangyu.github.io/software/clusterProfiler/">https://guangchuangyu.github.io/software/clusterProfiler/</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s2-1"><title>Human blood collection</title><p>As part of a COVID-19 observational study, peripheral blood samples were collected between March 31st and June 3rd of 2020 from 91 adults with SARS-CoV-2 infection, either after admission to Massachusetts General Hospital for the hospitalized cohort, or while at affiliated outpatient clinics for the outpatient cohort. Request for access to coded patient samples was reviewed by the Massachusetts Consortium for Pathogen Readiness (<ext-link ext-link-type="uri" xlink:href="https://masscpr.hms.harvard.edu/">https://masscpr.hms.harvard.edu/</ext-link>) and approved by the University of Massachusetts Medical School IRB (protocol #H00020836). Pediatric participants with COVID-19 or MIS-C were enrolled in the Massachusetts General Hospital Pediatric COVID-19 Biorepository (MGB IRB # 2020P000955). Healthy pediatric controls were enrolled in the Pediatric Biorepository (MGB IRB # 2016P000949). Samples were collected after obtaining consent from the patient if 18 years or older, or from the parent/guardian, plus assent when appropriate. Demographic, laboratory, and clinical outcome data were included with the coded samples. Samples from 86 adult blood donors and 17 pediatric blood donors were included as controls; these were either collected prior to the SARS-CoV-2 outbreak or from healthy individuals screened at a blood bank.</p></sec><sec id="s2-2"><title>Isolation of human peripheral blood mononuclear cells (PMBCs)</title><p>Human peripheral blood was diluted in an equal volume of RPMI-1640 (Gibco), overlaid on Lymphoprep (STEMCELL Technologies, #07851), and centrifuged at 500 x g at room temperature for 30 min. Mononuclear cells were washed three times with MACS buffer (0.5% BSA and 2 mM EDTA in PBS) and frozen in FBS containing 10% DMSO.</p></sec><sec id="s2-3"><title>Flow cytometry</title><p>PBMCs were first stained with Live and Dead violet viability kit (Invitrogen, L-34963). To detect surface molecules, cells were stained in MACS buffer with antibodies (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>) for 30 min at 4°C in the dark. To detect IL-13 or AREG, cells were stimulated with PMA and ionomycin (eBioscience, 00-4970-03) for 3 hr with Brefeldin A and Monensin (eBioscience, 00-4980-03) present during the stimulation. To detect transcription factors or cytokines, cells were fixed and permeabilized using Foxp3 staining buffer kit (eBioscience, 00-5523-00), then intracellular molecules were stained in permeabilization buffer with antibodies. Cells were detected on a BD Celesta flow cytometer using previously established gating strategies (<xref ref-type="bibr" rid="bib101">Wang et al., 2020</xref>). Cell subsets were identified using FlowJo software (Becton, Dickson and Company). Representative gating strategies are shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</p></sec><sec id="s2-4"><title>Bulk RNA-Seq library preparation</title><p>The sequencing libraries were prepared using CEL-Seq2 (<xref ref-type="bibr" rid="bib40">Hashimshony et al., 2016</xref>). RNA from sorted cells was extracted using TRIzol reagent (ThermoFisher, 15596018). Ten ng RNA was used for first strand cDNA synthesis using barcoded primers (the specific primers for each sample were listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). The second strand was synthesized by NEBNext Second Strand Synthesis Module (NEB, E6111L). The pooled dsDNA was purified with AMPure XP beads (Beckman Coulter, A63880), and subjected to in vitro transcription (IVT) using HiScribe T7 High Yield RNA Synthesis Kit (NEB, E2040S), then treated with ExoSAP-IT (Affymetrix, 78200). IVT RNA was fragmented using RNA fragmentation reagents (Ambion) and underwent another reverse transcription step using random hexamer RT primer-5’-GCC TTG GCA CCC GAG AAT TCC ANN NNN N-3’ to incorporate the second adapter. The final library was amplified with indexed primers: RP1 and RPI1 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>), and the bead purified library was quantified with 4,200 TapeStation (Agilent Technologies) and paired end sequenced on Nextseq 500 V2 (Illumina), Read 1: 15 cycles; index 1: 6 cycles; Read 2: 60 cycles.</p></sec><sec id="s2-5"><title>Analysis of RNA-Seq data</title><p>Pooled reads from PBMC-derived ILCs were separated by CEL-Seq2 barcodes, and demultiplexed reads from RNA-Seq of ILCs from lung (<xref ref-type="bibr" rid="bib4">Ardain et al., 2019</xref>), spleen, and intestine (<xref ref-type="bibr" rid="bib111">Yudanin et al., 2019</xref>), were downloaded from GSE131031 and GSE126107. Within the DolphinNext RNA-Seq pipeline (Revision 4) (<xref ref-type="bibr" rid="bib112">Yukselen et al., 2020</xref>), reads were aligned to the hg19 genome using STAR (version 2.1.6) (<xref ref-type="bibr" rid="bib28">Dobin et al., 2013</xref>) and counts of reads aligned to RefSeq genes were quantified using RSEM (version 1.3.1) (<xref ref-type="bibr" rid="bib62">Li and Dewey, 2011</xref>). Normalized transcript abundance in the form of TPMs were used to filter out low abundance transcripts with an average of &lt;3 TPMs across libraries. RSEM-generated expected counts were normalized and differential analysis was performed using DESeq2 (<xref ref-type="bibr" rid="bib67">Love et al., 2014</xref>) in R, with significant genes defined as a greater than 1.5-fold difference and an adjusted p-value &lt; 0.01. GO Enrichment Analysis was performed in R using the enrichGO function in the clusterProfiler R package (<xref ref-type="bibr" rid="bib110">Yu et al., 2012</xref>). Data were transformed using vsd within DESeq2 both for the heatmap visualization with ComplexHeatmap (<xref ref-type="bibr" rid="bib38">Gu et al., 2016</xref>) and for principal component analysis (PCA) with prcomp on the top 250 most variable genes. Normalized counts were generated for plotting using the counts command in DESeq2.</p></sec><sec id="s2-6"><title>Statistical analysis and data visualization</title><p>Data were prepared for analysis with tidyverse packages (<xref ref-type="bibr" rid="bib104">Wickham et al., 2019</xref>) and visualized using the ggplot2 (<xref ref-type="bibr" rid="bib103">Wickham, 2016</xref>), ggpubr (<xref ref-type="bibr" rid="bib50">Kassambara, 2020</xref>), and ComplexHeatmap (<xref ref-type="bibr" rid="bib38">Gu et al., 2016</xref>) packages, within the R computer software environment (version 4.0.2) (<xref ref-type="bibr" rid="bib85">R Development Core Team, 2020</xref>). Group differences were determined with pairwise, two-sided, Wilcoxon rank-sum tests, or Fisher’s exact test, as indicated, with Bonferroni correction for multiple comparisons. Multiple linear regression analyses were performed with dependent and independent variables as indicated in the text, using the lm function in R. Pairwise group comparisons on estimated marginal means generated from multiple linear regression were performed using the emmeans package (<xref ref-type="bibr" rid="bib105">Wieduwilt et al., 2020</xref>) in R, with multiple comparison correction using the Tukey adjustment. Multiple logistic regressions were performed using the glm function in R. Longitudinal follow-up analyses on pediatric COVID-19 and MIS-C was performed with linear mixed-effect models using lme4 (<xref ref-type="bibr" rid="bib10">Bates et al., 2015</xref>) in R with the equation: log<sub>2</sub> (lymphoid cell abundance) ~ Age + Sex + Group + Group:Follow_up + (1|Patient_ID). This model tested the effect of followup on ILC abundance in the pediatric COVID-19 and MIS-C groups while accounting for age, sex, and group. Statistical significance was determined with lmerTest (<xref ref-type="bibr" rid="bib56">Kuznetsova et al., 2017</xref>) in R, using the Satterthwarte’s degrees of freedom method. p &lt; 0.05 was considered significant. United States SARS-CoV-2 infection and mortality data were downloaded from (<xref ref-type="bibr" rid="bib18">CDC Case Surveillance Task Force, 2020</xref>) and cases with age group and outcome available were plotted by age group as indicated. Mortality rate was calculated by dividing the number of fatal cases by the total number of cases with known outcome in each age group as indicated.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Characteristics of adult blood donors, either hospitalized for COVID-19, treated for COVID-19 as outpatients, or SARS-CoV-2-uninfected controls</title><p>The first group of blood donors in this study included SARS-CoV-2-infected adults hospitalized for severe COVID-19 (N = 40), among whom 33 (82.5%) were admitted to the ICU, 32 (80%) required intubation with mechanical ventilation, and 7 (17.5%) died (<xref ref-type="table" rid="table1">Table 1</xref>). Aside from intubation, information regarding treatment during hospitalization was not available. This group had a mean age of 57.6 (range 24–83) and 60% were males. The second group consisted of adults infected with SARS-CoV-2 who were treated for COVID-19 as outpatients (N = 51). This group had a mean age of 36.8 years (range 23–77) and was 25.5% male (<xref ref-type="table" rid="table1">Table 1</xref>). Differences between these two SARS-CoV-2-infected groups, in terms of median age (<italic>P</italic> = 5.2 x 10<sup>–8</sup>), sex ratio (<italic>P</italic> = 3.7 x 10<sup>–3</sup>), and diagnosis of diabetes mellitus (p = 1.05 x 10<sup>–3</sup>), were consistent with established risk factors for severe COVID-19 (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="bibr" rid="bib2">Alkhouli et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Bunders and Altfeld, 2020</xref>; <xref ref-type="bibr" rid="bib39">Gupta et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Laxminarayan et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Mauvais-Jarvis, 2020</xref>; <xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Peckham et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Petrilli et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib95">Scully et al., 2020</xref>). Available information concerning ethnicity and race of the blood donors was insufficient for statistical comparisons among the groups (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2a</xref>). Finally, 86 adults who donated blood prior to the SARS-CoV-2 outbreak, or who were screened at a blood donation center, were included as controls for SARS-CoV-2 infection. The age of this group spanned the range of the two groups of SARS-CoV-2-infected people (mean age 50.9; range 23–79), and the percentage of males (55.8%) was similar to that of the group hospitalized for COVID-19 (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>). Complete information regarding ethnicity, race, and comorbidity was not available for control blood donors.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographic and clinical characteristics of adult blood donor groups.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Characteristic</th><th align="center" valign="bottom">ControlN = <bold>86</bold></th><th align="center" valign="bottom">HospitalizedN = <bold>40</bold></th><th align="center" valign="bottom">OutpatientN = <bold>51</bold></th></tr></thead><tbody><tr><td align="left" valign="bottom">Mean age (range) - years</td><td align="center" valign="bottom">50.9 (23–79)</td><td align="center" valign="bottom">57.6 (24–83)</td><td align="center" valign="bottom">36.8 (23–77)</td></tr><tr><td align="left" valign="bottom">Sex – number (%)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Male</td><td align="center" valign="bottom">48 (55.8)</td><td align="center" valign="bottom">24 (60)</td><td align="center" valign="bottom">13 (25.5)</td></tr><tr><td align="left" valign="bottom">Female</td><td align="center" valign="bottom">38 (44.2)</td><td align="center" valign="bottom">16 (40)</td><td align="center" valign="bottom">38 (74.5)</td></tr><tr><td align="left" valign="bottom">Mean symptom duration at sample collection (range) – days</td><td align="center" valign="bottom"/><td align="center" valign="bottom">21.8 (5–66)</td><td align="center" valign="bottom">26.9 (1–61)</td></tr><tr><td align="left" valign="bottom">Diabetes mellitus diagnosis – number (%)</td><td align="center" valign="bottom"/><td align="center" valign="bottom">11 (27.5)</td><td align="center" valign="bottom">1 (2)</td></tr><tr><td align="left" valign="bottom">ICU admission – number (%)</td><td align="center" valign="bottom"/><td align="center" valign="bottom">33 (82.5)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Intubation with mechanical ventilation – number (%)</td><td align="center" valign="bottom"/><td align="center" valign="bottom">32 (80)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Deaths – number (%)</td><td align="center" valign="bottom"/><td align="center" valign="bottom">7 (17.5)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mean time hospitalized (range) – days</td><td align="center" valign="bottom"/><td align="center" valign="bottom">34.2 (4–87)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Max lab value – mean (range)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">CRP – mg/L</td><td align="center" valign="bottom"/><td align="center" valign="bottom">228.6 (6.5–539.5)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">ESR – mm/h</td><td align="center" valign="bottom"/><td align="center" valign="bottom">89.0 (15–146)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">D-dimer – (ng/mL)</td><td align="center" valign="bottom"/><td align="center" valign="bottom">5700 (351–11923)</td><td align="center" valign="bottom"/></tr></tbody></table></table-wrap><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Age and sex of control and SARS-CoV-2-infected blood donors.</title><p>Age of the subjects is shown, along with the number of subjects and fraction male in each group, for adult (left) and pediatric (right) cohorts, as indicated. The p-values are from pairwise, two-sided, Wilcoxon rank-sum test for ages and Fisher’s exact test for fraction male, with Bonferroni correction for multiple comparisons. Adjusted p-values &lt; 0.05 are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig1-v2.tif"/></fig></sec><sec id="s3-2"><title>Characteristics of pediatric blood donors with COVID-19, MIS-C, or SARS-CoV-2-uninfected controls</title><p>Children are less likely than adults to have severe disease when infected with SARS-CoV-2 despite having viral loads as high as adults (<xref ref-type="bibr" rid="bib9">Bailey et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Heald-Sargent et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">LoTempio et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Lu et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Poline et al., 2020</xref>; <xref ref-type="bibr" rid="bib108">Yonker et al., 2020</xref>). Rarely, after SARS-CoV-2 clearance from the upper airways, children can develop severe Multisystem Inflammatory Syndrome in Children (MIS-C), a life-threatening condition distinct from COVID-19 that presents with high fevers and multiorgan injury, often including coronary aneurysms, ventricular failure, or myocarditis (<xref ref-type="bibr" rid="bib24">Cheung et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Feldstein et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Feldstein et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Licciardi et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Riphagen et al., 2020</xref>; <xref ref-type="bibr" rid="bib98">Verdoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib102">Whittaker et al., 2020</xref>).</p><p>The first cohort of pediatric blood donors in this study consisted of patients with COVID-19 who were treated in hospital (N = 11) or as outpatients (N = 8). The second cohort of pediatric blood donors was patients hospitalized for MIS-C (N = 11). Seventeen SARS-CoV-2-uninfected pediatric blood donors constituted a control group. No significant differences in age or percentage of males were detected among the pediatric COVID-19, MIS-C, or pediatric control groups (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s3-3"><title>Blood ILC abundance decreases exponentially across the lifespan and is sexually dimorphic</title><p>Lymphoid cell abundance in peripheral blood changes with age and is sexually dimorphic (<xref ref-type="bibr" rid="bib71">Márquez et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Patin et al., 2018</xref>). Previous studies reporting the effect of COVID-19 on the abundance of blood lymphoid cell subsets have not fully accounted for the association of age and sex with COVID-19 severity. To isolate the effect of COVID-19 on cell abundance from effects of age and sex, PBMCs were collected from 103 SARS-CoV-2-negative blood donors distributed from 2 to 79 years of age, with a nearly equal ratio of males to females (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2c</xref>). Abundance of lymphoid cell types was plotted by 20-year age groups (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), as well as by sex (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Lymphoid cell types assessed here included CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, ILCs, and FcγRIII (CD16)-positive NK cells. Like CD8<sup>+</sup> T cells, NK cells kill virus-infected cells using perforin and granzyme (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib23">Cherrier et al., 2018</xref>). Additionally, by binding virus-specific immunoglobulins that target virus-infected cells for antibody-dependent cellular cytotoxicity, CD16<sup>+</sup> NK cells link innate and acquired immunity (<xref ref-type="bibr" rid="bib3">Anegón et al., 1988</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Blood ILC abundance decreases exponentially across the lifespan mirroring the mortality rate from SARS-CoV-2 infection.</title><p>(<bold>A–B</bold>) Log<sub>2</sub> abundance per million lymphocytes of the indicated lymphoid cell populations in combined pediatric and adult control data plotted by 20 year bin or by sex, as indicated. Each dot represents an individual blood donor. Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR). The p-values are from two-sided, Wilcoxon rank-sum tests with Bonferroni correction for multiple comparisons. Adjusted p-values &lt; 0.05 are shown. (<bold>C</bold>) Case numbers and mortality rate within the indicated age ranges for cases reported in the United States between Jan 1, 2020, and June 6, 2021.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Combined demographic, clinical, and flow cytometry data for adult COVID-19 and control cohorts.</title><p>Data included in this file are associated with <xref ref-type="fig" rid="fig1">Figures 1</xref>—<xref ref-type="fig" rid="fig3">3</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="fig" rid="fig6">Figure 6</xref>; <xref ref-type="table" rid="table1 table2 table3 table4">Tables 1–4</xref>; and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2d,e</xref> . File name: Adult_COVIDandControl_data.xlsx.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74681-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Representative gating strategy.</title><p>(<bold>A</bold>) All cell subsets were first gated on lymphoid cells, singlets, live/dead, and CD45<sup>+</sup>. Lineage (Lin) markers included antibodies against: CD3, CD4, TCRαβ, TCRγδ, CD19, CD20, CD22, CD34, FcεRIα, CD11c, CD303, CD123, CD1a, and CD14. (<bold>B</bold>) ILCs were identified as Lin<sup>-</sup>CD56<sup>-</sup>CD16<sup>-</sup>CD127<sup>+</sup> (<bold>C</bold>) CD16<sup>+</sup> NK cells were identified as Lin<sup>-</sup>TBX21<sup>+</sup>CD16<sup>+</sup> (<bold>E</bold>) CD4<sup>+</sup> T cells were identified as Lin<sup>+</sup>CD4<sup>+</sup> (<bold>D</bold>), and CD8<sup>+</sup> T cells were identified as Lin<sup>+</sup>CD8<sup>+</sup>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig2-figsupp1-v2.tif"/></fig></fig-group><p>All cell types examined here were affected by age, but ILCs were the only subset with significant differences among all age groups, falling approximately twofold in median abundance every 20 years, with a greater than sevenfold decrease from the youngest to oldest age groups (p = 1.64 x 10<sup>–11</sup>) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). This magnitude decrease was unique to ILCs and corresponded inversely with the exponential increase in COVID-19 mortality with age (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). In addition, both ILCs and CD4<sup>+</sup> T cells were less abundant in males (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These findings highlight the importance of accounting for effects of age and sex when assessing group differences in lymphoid cell abundance, particularly in the context of a disease such as COVID-19 that disproportionately affects older males (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>).</p></sec><sec id="s3-4"><title>Adults hospitalized with COVID-19 have fewer total lymphocytes even after accounting for effects of age and sex</title><p>Severe COVID-19 is associated with lymphopenia (<xref ref-type="bibr" rid="bib22">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Huang and Pranata, 2020</xref>; <xref ref-type="bibr" rid="bib113">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib114">Zhao et al., 2020</xref>) but it remains unclear if this effect is due to reduction in particular lymphoid cell subpopulations, or whether this effect is explained by the more advanced age and higher proportion of males among people with severe COVID-19. As a first step to assess the specificity of lymphocyte depletion, the effect of COVID-19 on total lymphocyte abundance was addressed with multiple linear regression. After accounting for effects of age and sex, individuals hospitalized with severe COVID-19 had 1.33-fold (95% CI: 1.49–1.19; p = 1.22 x 10<sup>–6</sup>) fewer total lymphocytes among PBMCs than did controls (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2d</xref>). Lymphocyte abundance in people infected with SARS-CoV-2 who were treated as outpatients was not different from controls (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2d</xref>). In addition, total lymphocytes decreased with age and were less abundant in males (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2d</xref>). Subsequent analyses of lymphoid cell subsets took into account the depletion in total lymphocytes associated with COVID-19 by assessing lymphoid subsets as a fraction of total lymphocytes.</p></sec><sec id="s3-5"><title>After accounting for age and sex, only innate lymphoid cells are depleted in severe COVID-19</title><p>To determine whether there were independent associations between lymphoid cell subsets and COVID-19, multiple linear regression was performed on the abundance of lymphoid cell subsets, with age, sex, and group (control, hospitalized, and outpatient) as independent variables. Across all three groups of adult blood donors, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and ILCs decreased with age, while CD16<sup>+</sup> NK cells increased with age, and both CD4<sup>+</sup> T cells and ILCs were less abundant in males (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Change in cell abundance due to age, sex, and COVID-19 severity fold difference (log<sub>2</sub>) [± 95% CI].</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"> </th><th align="left" valign="bottom">CD4<sup>+</sup> T<xref ref-type="table-fn" rid="table2fn2">*</xref></th><th align="left" valign="bottom">ILC<xref ref-type="table-fn" rid="table2fn2">*</xref></th><th align="left" valign="bottom">CD8<sup>+</sup> T<xref ref-type="table-fn" rid="table2fn2">*</xref></th><th align="left" valign="bottom">CD16<sup>+</sup> NK<xref ref-type="table-fn" rid="table2fn2">*</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom">Age</td><td align="left" valign="bottom">–0.012***</td><td align="left" valign="bottom">–0.043***</td><td align="left" valign="bottom">–0.009*</td><td align="left" valign="bottom">0.021***</td></tr><tr><td align="left" valign="bottom"> </td><td align="left" valign="bottom">[–0.018,–0.005]</td><td align="left" valign="bottom">[–0.053,–0.033]</td><td align="left" valign="bottom">[–0.016,–0.002]</td><td align="left" valign="bottom">[0.010, 0.032]</td></tr><tr><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">–0.409***</td><td align="left" valign="bottom">–0.334*</td><td align="left" valign="bottom">–0.177</td><td align="left" valign="bottom">0.184</td></tr><tr><td align="left" valign="bottom"> </td><td align="left" valign="bottom">[–0.618,–0.201]</td><td align="left" valign="bottom">[–0.659,–0.010]</td><td align="left" valign="bottom">[–0.406, 0.051]</td><td align="left" valign="bottom">[–0.169, 0.538]</td></tr><tr><td align="left" valign="bottom">Hospitalized</td><td align="left" valign="bottom">0.168</td><td align="left" valign="bottom">–0.835***</td><td align="left" valign="bottom">0.227</td><td align="left" valign="bottom">–1.205***</td></tr><tr><td align="left" valign="bottom"> </td><td align="left" valign="bottom">[–0.084, 0.421]</td><td align="left" valign="bottom">[–1.228,–0.441]</td><td align="left" valign="bottom">[–0.050, 0.503]</td><td align="left" valign="bottom">[–1.633,–0.778]</td></tr><tr><td align="left" valign="bottom">Outpatient</td><td align="left" valign="bottom">0.332*</td><td align="left" valign="bottom">–0.088</td><td align="left" valign="bottom">–0.023</td><td align="left" valign="bottom">–0.522*</td></tr><tr><td align="left" valign="bottom"> </td><td align="left" valign="bottom">[0.082, 0.581]</td><td align="left" valign="bottom">[–0.478, 0.302]</td><td align="left" valign="bottom">[–0.298, 0.253]</td><td align="left" valign="bottom">[–0.948,–0.095]</td></tr><tr><td align="left" valign="bottom">R<sup>2</sup></td><td align="left" valign="bottom">0.275</td><td align="left" valign="bottom">0.478</td><td align="left" valign="bottom">0.070</td><td align="left" valign="bottom">0.232</td></tr></tbody></table><table-wrap-foot><fn><p>*p&lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</p></fn><fn id="table2fn2"><label>*</label><p>per 10<sup>6</sup> lymphocytes.</p></fn></table-wrap-foot></table-wrap><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Innate lymphoid cells are depleted in adults hospitalized with COVID-19 and ILC abundance correlates inversely with disease severity.</title><p>(<bold>A</bold>) Effect of age (X-axis) on log<sub>2</sub> abundance per million total lymphocytes of the indicated lymphoid cell populations (Y-axis), as determined by the regression analysis in <xref ref-type="table" rid="table2">Table 2</xref>. Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. The p-values are from the regression analysis for comparisons to the control group. (<bold>B</bold>) Log<sub>2</sub> abundance per million lymphocytes of the indicated lymphoid cell populations, shown as estimated marginal means with 95% CI, generated from the multiple linear regressions in <xref ref-type="table" rid="table2">Table 2</xref>, and averaged across age and sex. The p-values represent pairwise comparisons on the estimated marginal means, adjusted for multiple comparisons with the Tukey method. Adjusted p-values &lt; 0.05 are shown. (<bold>C</bold>) Association of the indicated clinical parameters with log<sub>2</sub> abundance of ILCs per million lymphoid cells. Regression lines are from simplified multiple regression models to permit visualization on a two-dimensional plane. Shading represents the 95% CI. Results of the full models accounting for effects of both age and sex, are reported in <xref ref-type="table" rid="table4">Table 4</xref> and the text.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Innate lymphoid cell precursors (ILCPs) decrease with age and are depleted in patients hospitalized with COVID-19.</title><p>(<bold>A</bold>) Representative gating for ILCP identification in PBMCs. Cells were first gated on lymphoid cells, singlets, live/dead, and CD45<sup>+</sup>. Lineage (Lin) markers included antibodies against: CD3, CD4, TCRαβ, TCRγδ, CD19, CD20, CD22, CD34, FcεRIα, CD11c, CD303, CD123, CD1a, and CD14. (<bold>B</bold>) Effect of age (X-axis) on log<sub>2</sub> ILCP abundance per million total lymphocytes (Y-axis). Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. The p-values are from the regression analysis for comparisons to the control group. (<bold>C</bold>) Lymphoid cell abundance by group, shown as estimated marginal means with 95% CI, generated from the multiple linear regressions in (<bold>B</bold>), and averaged across age and sex. The p-values represent pairwise comparisons on the estimated marginal means, adjusted for multiple comparisons with the Tukey method.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Association of blood ILC depletion with COVID-19 severity in an independent cohort of adults.</title><p>(<bold>A</bold>) Effect of age (X-axis) on log<sub>2</sub> ILC abundance per million total lymphocytes (Y-axis) in adult controls from this paper and patients with COVID-19 from <xref ref-type="bibr" rid="bib55">Kuri-Cervantes et al., 2020</xref>. Patients were stratified into two groups by disease severity. The first group included patients maintained on room air or treated with O2 by nasal cannula. The second group included those with ARDS. Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. The p-values are from the regression analysis for comparisons to the control group. (<bold>B</bold>) Table of regression coefficients for log<sub>2</sub> fold difference in ILC abundance for patients with COVID-19, in comparison to the adult healthy control cohort, adjusted for effects of age and sex.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig3-figsupp2-v2.tif"/></fig></fig-group><p>When effects of age and sex were held constant, adults hospitalized with COVID-19 had 1.78-fold fewer ILCs (95% CI: 2.34–1.36; p = 4.55 x 10<sup>–5</sup>) and 2.31-fold fewer CD16<sup>+</sup> natural killer (NK) cells (95% CI: 3.1–1.71; p = 1.04 x 10<sup>–7</sup>), as compared to controls (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3B</xref>). Similar effects were also seen with ILC precursors (ILCP) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Neither CD4<sup>+</sup> T cells nor CD8<sup>+</sup> T cells were depleted further than expected for age and sex (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3B</xref>). As compared with controls, SARS-CoV-2-infected adults with less severe COVID-19 who were treated as outpatients had no reduction in ILCs, but 1.44-fold fewer CD16<sup>+</sup> NK cells (95% CI: 1.93–1.07; p = 0.018), and 1.26-fold higher CD4<sup>+</sup> T cells (95% CI: 1.06–1.5; p = 9.59 x 10<sup>–3</sup>) (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3B</xref>). As these analyses were performed on lymphoid cell abundance normalized to total lymphocyte number, it is possible that T cells were not lower in patients hospitalized with COVID-19 because the amount of depletion was not in excess of the change in total lymphocytes. However, the cell-type-specific results remained unchanged even when the analyses were repeated using the less stringent threshold of normalizing to total PBMC number (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2e</xref>).</p><p>When data from an independent, previously published cohort (<xref ref-type="bibr" rid="bib55">Kuri-Cervantes et al., 2020</xref>) were analyzed to account for total lymphocyte abundance, age, and sex, people hospitalized with acute respiratory distress syndrome due to COVID-19, had 1.7-fold fewer ILCs (95% CI: 2.38–1.22; p = 0.002) than controls (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Also consistent with the main adult cohort studied here, ILC abundance was not significantly reduced in the group of patients with less severe disease (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p></sec><sec id="s3-6"><title>Odds of hospitalization in adults infected with SARS-CoV-2 increases with decreasing number of ILCs</title><p>Multiple logistic regression was used next to determine whether differences in abundance of any lymphoid cell subset was associated with odds of hospitalization in people infected with SARS-CoV-2. The adjusted odds ratio was calculated using lymphoid cell subset abundance, age, sex, diagnosis of diabetes mellitus, and duration of symptoms at the time of blood draw, each as independent variables. Abundance of ILCs, but not of CD16<sup>+</sup> NK cells, CD4<sup>+</sup> T cells, or CD8<sup>+</sup> T cells was associated with odds of hospitalization: the odds ratio for hospitalization, adjusted for age, sex, diagnosis of diabetes mellitus, and symptom duration, was 0.454 (95%CI: 0.213–0.808; p = 0.018), an increase of 54.6% for each twofold decrease in ILC abundance (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Odds of hospitalization<xref ref-type="table-fn" rid="table3fn1">*</xref>.</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"><bold>Cell count</bold><xref ref-type="table-fn" rid="table3fn2"><sup>†</sup></xref></td><td align="left" valign="bottom"><bold>Odds ratio</bold><xref ref-type="table-fn" rid="table3fn3"><sup>‡</sup></xref></td><td align="left" valign="bottom"><bold>95% Confidence interval</bold></td><td align="left" valign="bottom"><bold>p-value</bold></td></tr><tr><td align="left" valign="bottom">CD4<sup>+</sup> T</td><td align="char" char="." valign="bottom">0.576</td><td align="char" char="ndash" valign="bottom">0.211–1.28</td><td align="char" char="." valign="bottom">0.198</td></tr><tr><td align="left" valign="bottom">ILC</td><td align="char" char="." valign="bottom">0.454</td><td align="char" char="ndash" valign="bottom">0.213–0.808</td><td align="char" char="." valign="bottom">0.018</td></tr><tr><td align="left" valign="bottom">CD8<sup>+</sup> T</td><td align="char" char="." valign="bottom">1.2</td><td align="char" char="ndash" valign="bottom">0.584–3.06</td><td align="char" char="." valign="bottom">0.652</td></tr><tr><td align="left" valign="bottom">CD16<sup>+</sup> NK</td><td align="char" char="." valign="bottom">0.841</td><td align="char" char="ndash" valign="bottom">0.538–1.27</td><td align="char" char="." valign="bottom">0.412</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><label>*</label><p>Adjusted for age, sex, diagnosis of diabetes mellitus, and symptom duration at time of sample collection.</p></fn><fn id="table3fn2"><label>†</label><p>per 10<sup>6</sup> lymphocytes.</p></fn><fn id="table3fn3"><label>‡</label><p>per twofold increase in cell population abundance.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-7"><title>Duration of hospital stay in adults with COVID-19 increases with decreasing ILC abundance</title><p>The relationship between lymphoid cell abundance and duration of hospitalization was assessed to determine whether the association between ILC abundance and COVID-19 severity extended to clinical outcomes within the hospitalized adults. This relationship was assessed with multiple linear regression, including age, sex, and cell abundance as independent variables. Holding age and sex constant, abundance of ILCs, but not of CD16<sup>+</sup> NK cells, CD4<sup>+</sup> T cells, or CD8<sup>+</sup> T cells, was associated with length of time in the hospital: each twofold decrease in ILC abundance was associated with a 9.38-day increase in duration of hospital stay (95% CI: 15.76–3.01; p = 0.0054) (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Association of cell type abundance with time in hospital and laboratory values<xref ref-type="table-fn" rid="table4fn2">*</xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Cell count<xref ref-type="table-fn" rid="table4fn3"><sup>†</sup></xref></th><th align="left" valign="bottom">Days hospitalized</th><th align="left" valign="bottom">CRP (mg/L)<xref ref-type="table-fn" rid="table4fn4"><sup>‡</sup></xref></th><th align="left" valign="bottom">ESR (mm/h)<xref ref-type="table-fn" rid="table4fn4"><sup>‡</sup></xref></th><th align="left" valign="bottom">D-dimer (ng/mL)<xref ref-type="table-fn" rid="table4fn4"><sup>‡</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="2" valign="bottom"><bold>CD4<sup>+</sup> T</bold></td><td align="left" valign="bottom">–10.843</td><td align="left" valign="bottom">–3.335</td><td align="left" valign="bottom">–2.674</td><td align="left" valign="bottom">–1868.847*</td></tr><tr><td align="left" valign="bottom">[–22.511, 0.825]</td><td align="left" valign="bottom">[–56.162, 49.492]</td><td align="left" valign="bottom">[–23.840, 18.492]</td><td align="left" valign="bottom">[–3375.630, –362.063]</td></tr><tr><td align="left" rowspan="2" valign="bottom"><bold>ILC</bold></td><td align="left" valign="bottom">–9.381**</td><td align="left" valign="bottom">–46.288***</td><td align="left" valign="bottom">–11.035*</td><td align="left" valign="bottom">–1098.515*</td></tr><tr><td align="left" valign="bottom">[–15.755,–3.008]</td><td align="left" valign="bottom">[–71.337, –21.238]</td><td align="left" valign="bottom">[-21.936,–0.134]</td><td align="left" valign="bottom">[–1932.842, –264.188]</td></tr><tr><td align="left" rowspan="2" valign="bottom"><bold>CD8<sup>+</sup> T</bold></td><td align="left" valign="bottom">3.366</td><td align="left" valign="bottom">32.247</td><td align="left" valign="bottom">15.317</td><td align="left" valign="bottom">486.192</td></tr><tr><td align="left" valign="bottom">[–8.992, 15.724]</td><td align="left" valign="bottom">[–16.509, 81.003]</td><td align="left" valign="bottom">[–4.127, 34.761]</td><td align="left" valign="bottom">[–1049.836, 2022.221]</td></tr><tr><td align="left" rowspan="2" valign="bottom"><bold>CD16<sup>+</sup> NK</bold></td><td align="left" valign="bottom">–4.775</td><td align="left" valign="bottom">–14.619</td><td align="left" valign="bottom">–5.159</td><td align="left" valign="bottom">–404.873</td></tr><tr><td align="left" valign="bottom">[–11.251, 1.701]</td><td align="left" valign="bottom">[–44.011, 14.774]</td><td align="left" valign="bottom">[–16.809, 6.491]</td><td align="left" valign="bottom">[–1316.261, 506.516]</td></tr></tbody></table><table-wrap-foot><fn><p>* p&lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001.</p></fn><fn id="table4fn2"><label>*</label><p>coefficients are for each two-fold increase in cell population abundance, adjusted for age and sex [ ± 95% CI].</p></fn><fn id="table4fn3"><label>†</label><p>per 10<sup>6</sup> lymphoid cells.</p></fn><fn id="table4fn4"><label>‡</label><p>Maximum lab value recorded during course of hospitalization.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-8"><title>ILC abundance correlates inversely with markers of inflammation in adults hospitalized with COVID-19</title><p>To further characterize the extent to which lymphoid cell abundance predicted COVID-19 severity, multiple regression with age, sex, and cell abundance, as independent variables, was performed on peak blood levels of inflammation markers indicative of COVID-19 severity: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and the fibrin degradation product D-dimer (<xref ref-type="bibr" rid="bib34">Gallo Marin et al., 2021</xref>; <xref ref-type="bibr" rid="bib39">Gupta et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Luo et al., 2020</xref>; <xref ref-type="bibr" rid="bib113">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib116">Zhou et al., 2020</xref>). Holding age and sex constant, each two-fold decrease in ILC, but not in CD16<sup>+</sup> NK cell, CD4<sup>+</sup> T cell, or CD8<sup>+</sup> T cell abundance, was associated with a 46.29 mg/L increase in blood CRP (95% CI: 71.34–21.24; p = 6.25 x 10<sup>–4</sup>) and 11.04 mm/hr increase in ESR (95% CI: 21.94–0.13; p = 0.047) (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="table" rid="table4">Table 4</xref>). Abundance of both ILCs and CD4<sup>+</sup> T cells was associated with blood levels of D-dimer, with each two-fold decrease in cell abundance associated with an increase in D-dimer by 1098.52 ng/mL (95% CI: 1932.84–264.19; p = 0.011) and 1868.85 ng/mL (95% CI: 3375.63–362.06; p = 0.016), respectively (<xref ref-type="table" rid="table4">Table 4</xref>).</p></sec><sec id="s3-9"><title>ILCs are depleted in children and young adults with COVID-19 or MIS-C</title><p>Given the decline in ILC abundance with age (<xref ref-type="fig" rid="fig2">Figures 2A</xref> and <xref ref-type="fig" rid="fig3">3A</xref>, and <xref ref-type="table" rid="table2">Table 2</xref>), and the inverse relationship between ILC abundance and disease severity in adults (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, and <xref ref-type="table" rid="table3 table4">Tables 3 and 4</xref>), it was hypothesized that children as a group have less severe COVID-19 because ILC abundance is higher at younger ages, and that pediatric cases with symptomatic SARS-CoV-2 infection, or with MIS-C, are accompanied by significantly lower numbers of ILCs. To test these hypotheses, the abundance of lymphoid cell subsets in pediatric COVID-19 or MIS-C was compared with that from pediatric controls, using multiple linear regression with age, sex, and group as independent variables. Consistent with the findings in adults, blood ILCs in the pediatric cohort decreased with age (<xref ref-type="table" rid="table5">Table 5</xref> and <xref ref-type="fig" rid="fig4">Figure 4A</xref>), demonstrating that the decrease in ILC abundance across the lifespan is already evident within the first two decades of life. In contrast, significant change over this age range was not detected in the abundance of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, or CD16<sup>+</sup> NK cells (<xref ref-type="table" rid="table5">Table 5</xref> and <xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>ILCs are depleted in children with COVID-19 or MIS-C.</title><p>(<bold>A</bold>) Effect of age (X-axis) on log<sub>2</sub> abundance per million lymphocytes of the indicated lymphoid cell populations (Y-axis), as determined by the regression analysis in <xref ref-type="table" rid="table5">Table 5</xref>. Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. The p-values are from the regression analysis for comparisons to the control group. (<bold>B</bold>) Log<sub>2</sub> abundance per million lymphocytes of the indicated lymphoid cell populations, shown as estimated marginal means with 95% CI, generated from the multiple linear regressions in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2g</xref> that included the combined pediatric and adult control data, and averaged across age and sex. The p-values represent pairwise comparisons on the estimated marginal means, adjusted for multiple comparisons with the Tukey method. Adjusted p-values &lt; 0.05 are shown. (<bold>C</bold>) Association of CRP with log<sub>2</sub> abundance of ILCs per million lymphocytes. Shading represents the 95% CI. Each dot represents a single blood donor, orange for COVID-19, magenta for MIS-C. The p-value is for the effect of ILC abundance on CRP as determined by linear regression. (<bold>D</bold>) Log<sub>2</sub> ILC abundance per million lymphocytes in longitudinal pairs of samples collected during acute presentation and during follow-up, from individual children with COVID-19 or MIS-C. Each pair of dots connected by a line represents an individual blood donor. The p-values are for change in ILC abundance at follow-up, as determined with a linear mixed model, adjusting for age, sex, and group, and with patient as a random effect. (<bold>E</bold>) Effect of time to follow-up (X-axis) on log<sub>2</sub> abundance per million lymphocytes of the indicated lymphoid cell populations (Y-axis). The p-values are for the difference between the COVID-19 and MIS-C follow-up groups, independent of time to follow-up as determined by multiple linear regression. Shading represents the 95% CI.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Combined demographic, clinical, and flow cytometry data for pediatric COVID-19, MIS-C, and control cohorts.</title><p>Data included in this file are associated with <xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig4">4</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>; <xref ref-type="table" rid="table5">Table 5</xref>, and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2f,g</xref>. File name: Pediatric_ COVID_MISC_andControl_data.xlsx.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74681-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effects of pediatric COVID-19 and MIS-C on blood lymphoid cell subsets in comparison to full combined adult and pediatric control group.</title><p>Effect of age (X-axis) on log<sub>2</sub> abundance per million total lymphocytes of the indicated lymphoid cell populations (Y-axis). Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. The p-values are from the regression analysis for comparisons to the control group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>T cells increase during follow-up from MIS-C.</title><p>Log<sub>2</sub> ILC abundance per million lymphocytes in longitudinal pairs of samples collected during acute presentation and during follow-up, from individual children with COVID-19 or MIS-C. The p-values are for change in ILC abundance at follow-up, as determined with linear mixed models, adjusting for age, sex, and group, and with patient as a random effect. Differences in sample size among cell types was due to limited sample availability.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig4-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Change in pediatric cohort cell abundance due to age, sex, and group.</title><p>Fold difference (log<sub>2</sub>) [± 95% CI].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">CD4<sup>+</sup>T<xref ref-type="table-fn" rid="table5fn2"><bold>*</bold></xref></th><th align="left" valign="bottom">ILC<xref ref-type="table-fn" rid="table5fn2">*</xref></th><th align="left" valign="bottom">CD8<sup>+</sup>T<xref ref-type="table-fn" rid="table5fn2">*</xref></th><th align="left" valign="bottom">CD16<sup>+</sup>NK<xref ref-type="table-fn" rid="table5fn2">*</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom">Age</td><td align="left" valign="bottom">–0.004</td><td align="left" valign="bottom">–0.083**</td><td align="left" valign="bottom">0.012</td><td align="left" valign="bottom">0.004</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">[–0.027, 0.019]</td><td align="left" valign="bottom">[–0.135,–0.032]</td><td align="left" valign="bottom">[–0.014, 0.039]</td><td align="left" valign="bottom">[–0.060, 0.068]</td></tr><tr><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">–0.219</td><td align="left" valign="bottom">–0.027</td><td align="left" valign="bottom">0.060</td><td align="left" valign="bottom">–0.343</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">[–0.492, 0.054]</td><td align="left" valign="bottom">[–0.640, 0.586]</td><td align="left" valign="bottom">[–0.249, 0.370]</td><td align="left" valign="bottom">[–1.098, 0.413]</td></tr><tr><td align="left" valign="bottom">COVID</td><td align="left" valign="bottom">0.018</td><td align="left" valign="bottom">–0.754*</td><td align="left" valign="bottom">–0.088</td><td align="left" valign="bottom">0.416</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">[–0.290, 0.327]</td><td align="left" valign="bottom">[–1.447,–0.061]</td><td align="left" valign="bottom">[–0.432, 0.257]</td><td align="left" valign="bottom">[–0.424, 1.257]</td></tr><tr><td align="left" valign="bottom">MIS-C</td><td align="left" valign="bottom">–0.678***</td><td align="left" valign="bottom">–1.098**</td><td align="left" valign="bottom">–0.503*</td><td align="left" valign="bottom">–0.498</td></tr><tr><td align="left" valign="bottom"> </td><td align="left" valign="bottom">[–1.028,–0.328]</td><td align="left" valign="bottom">[–1.884,–0.313]</td><td align="left" valign="bottom">[–0.904,–0.101]</td><td align="left" valign="bottom">[–1.479, 0.483]</td></tr><tr><td align="left" valign="bottom">R<sup>2</sup></td><td align="left" valign="bottom">0.359</td><td align="left" valign="bottom">0.342</td><td align="left" valign="bottom">0.169</td><td align="left" valign="bottom">0.106</td></tr></tbody></table><table-wrap-foot><fn><p>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001</p></fn><fn id="table5fn2"><label>*</label><p><sup>a</sup>per 10<sup>6</sup> lymphocytes</p></fn></table-wrap-foot></table-wrap><p>Among pediatric patients with COVID-19, no difference in abundance of the lymphoid cell subsets was associated with hospitalization (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2f</xref>), so all pediatric patients treated for COVID-19 were analyzed as a single group. After accounting for effects of age and sex, pediatric patients with COVID-19 had 1.69-fold fewer ILCs (95% CI: 2.73–1.04; p = 0.034) than controls (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="table" rid="table5">Table 5</xref>). Neither CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, nor CD16<sup>+</sup> NK cells were depleted in pediatric COVID-19 patients (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="table" rid="table5">Table 5</xref>).</p><p>As with pediatric COVID-19, ILCs were also lower in MIS-C, with 2.14-fold fewer ILCs (95% CI: 3.69–1.24; p = 0.007) than controls (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="table" rid="table5">Table 5</xref>). However, unlike pediatric COVID-19, individuals with MIS-C had reduced numbers of T cells as compared with pediatric controls, with 1.6-fold fewer CD4<sup>+</sup> T cells (95% CI: 2.04–1.26; p = 3.28 × 10<sup>–4</sup>) and 1.42-fold fewer CD8<sup>+</sup> T cells (95% CI: 1.87–1.07; p = 0.016) (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="table" rid="table5">Table 5</xref>). Depletion of T cells, then, distinguished MIS-C from both pediatric and adult COVID-19. Additionally, consistent with the finding in adults hospitalized with COVID-19 (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="table" rid="table4">Table 4</xref>), after accounting for effect of group, each twofold decrease in ILC abundance in pediatric patients hospitalized with COVID-19 or MIS-C was associated with a 40.5 mg/L increase in blood CRP (95% CI: 77.87–3.13; p = 0.035) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), and no such association was detected with CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, or CD16<sup>+</sup> NK cells.</p><p>The above analysis of lymphoid cell subsets in pediatric COVID-19 and MIS-C was performed in comparison to pediatric controls alone. Results were essentially unchanged when multiple linear regression was repeated with combined pediatric and adult control groups (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2g</xref>).</p></sec><sec id="s3-10"><title>Pediatric MIS-C is distinguished from COVID-19 by recovery of ILCs during follow-up</title><p>The availability of follow-up samples in this pediatric cohort provided the opportunity to assess the abundance of lymphoid subsets after recovery from illness. To this end, a linear mixed model was fit to determine the change in ILC abundance from acute illness to follow-up in 10 individuals (5 COVID-19 and 5 MIS-C) for whom both acute and follow-up samples were available. After accounting for effects of age, sex, and group, individuals recovering from MIS-C had a 2.39-fold increase in ILC abundance (95% CI: 1.49–3.81; p = 6.6 × 10<sup>–3</sup>) but there was no significant change in ILC abundance for individuals recovering from COVID-19 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells, which were depleted in MIS-C but not in COVID-19, also increased during recovery from MIS-C and remained unchanged during recovery from COVID-19 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p>The relationship between time to follow-up and lymphoid cell abundance was then examined for all available follow-up samples whether or not a paired sample from the acute illness was available (COVID-19, N = 14; MIS-C, N = 7). This analysis found no relationship between time to follow-up and abundance of any lymphoid subset, and that individuals recovering from MIS-C had 2.28-fold more ILCs (95% CI: 1.11–4.69; p = 0.0265) than individuals recovering from COVID-19 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Of note, ILC abundance rebounded by 2 months of follow-up for the MIS-C patients, whereas ILC abundance still had not rebounded after 9 months of follow-up for the COVID-19 patients. There was no difference between the follow-up groups in CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, or CD16<sup>+</sup> NK cells. Interestingly, prior to being hospitalized with MIS-C, only one of these patients had COVID-19 symptoms and, despite low ILC abundance in the COVID-19 follow-up cohort, only 28.6% of this group had been ill enough to require hospitalization (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b</xref>).</p><p>Differences between COVID-19 and MIS-C in regard to T cell depletion and ILC recovery during follow-up indicate that the underlying processes causing lower ILC abundance in these two SARS-CoV-2-associated diseases are different.</p></sec><sec id="s3-11"><title>Blood ILCs resemble homeostatic ILCs isolated from lung</title><p>In response to the above results with blood ILCs, attempts were made to profile ILCs from the lungs of people with fatal COVID-19, but isolation of ILCs from available samples was unsuccessful. Given that ILCs circulate from tissues to the bloodstream via the thoracic duct (<xref ref-type="bibr" rid="bib15">Buggert et al., 2020</xref>), blood ILC levels might reflect tissue-resident cells and serve as a surrogate for lung ILCs. While ILCs might be decreased in the blood as a result of sequestration within the COVID-19-damaged lung (<xref ref-type="bibr" rid="bib4">Ardain et al., 2019</xref>), reduced numbers of ILCs within the intestinal lamina propria of people living with HIV-1 is paralleled by reduction in blood ILCs (<xref ref-type="bibr" rid="bib101">Wang et al., 2020</xref>).</p><p>Given the inability to assess lung samples from people with COVID-19, RNA sequencing (RNA-Seq) was performed on blood ILCs from nine healthy controls and these data were compared to previously published RNA-Seq profiles of ILCs sorted from lung, spleen, and intestine (<xref ref-type="bibr" rid="bib4">Ardain et al., 2019</xref>; <xref ref-type="bibr" rid="bib111">Yudanin et al., 2019</xref>). Unbiased principal component analysis demonstrated overlap of blood ILCs with ILCs from the lung, with clear separation from ILCs of jejunum or spleen origin (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Blood ILCs are transcriptionally similar to lung ILCs.RNA-Seq of ILCs sorted from blood of 9 SARS-CoV-2-uninfected controls in comparison to RNA-Seq data of ILCs sorted from jejunum, lung, and spleen.</title><p>(<bold>A</bold>) PCA plot of first two principal components calculated from the top 250 most variable genes across all samples. Each dot represents an individual sample with blue for ILCs sorted from blood, green for lung, yellow for jejunum, and grey for spleen. (<bold>B</bold>) Heatmap of 355 genes differentially expressed (fold-change &gt;1.5, padj &lt;0.01 as determined with DESeq2) between either blood or lung ILCs and ILCs from the other tissues. (<bold>C</bold>) Select genes from (<bold>B</bold>) plotted as DESeq2 normalized counts. Each dot represents an individual sample with blue for ILCs sorted from blood, green for lung, yellow for jejunum, and grey for spleen. Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles, respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig5-v2.tif"/></fig><p>Based on expression of characteristic transcription factors and specific inducible cytokines, ILCs are classified into ILC1, ILC2, and ILC3 subsets that are analogous to T<sub>H</sub>1, T<sub>H</sub>2, and T<sub>H</sub>17 cells, respectively (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib23">Cherrier et al., 2018</xref>; <xref ref-type="bibr" rid="bib99">Vivier et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Yudanin et al., 2019</xref>). A total of 355 genes were consistently differentially expressed (fold-change &gt;1.5, padj &lt;0.01) when either blood or lung ILCs were compared to ILCs from the other tissues (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Gene ontology analysis demonstrated enrichment for terms associated with type two immunity (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2h</xref>). Genes significantly higher in both blood and lung ILCs included the ILC2-defining genes GATA3 and PTGDR2 (CRTH2), as well as other genes important for ILC development such as TCF7 (<xref ref-type="bibr" rid="bib106">Yang et al., 2013</xref>; <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>).</p><p>TCF7- and CRTH2-encoded proteins were detected in blood ILCs by flow cytometry, confirming the RNA signature of ILC2s (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). To assess the function of blood ILCs, PBMCs were stimulated with PMA and ionomycin, and assayed by flow cytometry for production of IL-13 after intracellular cytokine staining and gating on ILCs. IL-13 was detected in the stimulated ILC population (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), demonstrating that the majority of blood ILCs function as ILC2s. Additionally, the blood ILCs produced amphiregulin (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), a protein implicated in the promotion of disease tolerance by ILCs in animal models (<xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Jamieson et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Peripheral blood ILCs exhibit homeostatic ILC2 functions.</title><p>(<bold>A–B</bold>) Flow cytometry for the indicated proteins. Cells in (<bold>A</bold>) were assayed at steady-state and cells in (<bold>B</bold>) were assayed either at steady-state or after stimulation with PMA and ionomycin, as indicated. Detection of surface proteins was performed on ILCs gated as Lin<sup>-</sup>CD56<sup>-</sup>CD127<sup>+</sup> and detection of intracellular proteins was performed on ILCs gated as Lin<sup>-</sup>TBX21<sup>-</sup>CD127<sup>+</sup>. (<bold>C</bold>) Percent of AREG<sup>+</sup> ILCs in blood of control blood donors after stimulation with PMA and ionomycin and gated as Lin<sup>-</sup>TBX21<sup>-</sup>CD127<sup>+</sup>. Each dot represents an individual blood donor (N Female = 13, N Male = 25). Boxplots represent the distribution of the data with the center line drawn through the median with the upper and lower bounds of the box at the 75th and 25th percentiles respectively. The upper and lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range (IQR). The p-value is from a two-sided, Wilcoxon rank-sum test. (<bold>D</bold>) Log<sub>2</sub> percent AREG<sup>+</sup> ILCs in blood of controls or people hospitalized with COVID-19 after stimulation with PMA and ionomycin and gated as Lin<sup>-</sup>TBX21<sup>-</sup>. Data shown as estimated marginal means with 95% CI, generated from the multiple linear regression reported in the text and averaged across age and sex. The p-value is from the regression analysis.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Amphiregulin (AREG) flow cytometry data presented in <xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title><p>File name: AREG_in_ILCs.xlsx.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74681-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Males have lower percent AREG<sup>+</sup> ILCs, and lower AREG MFI in ILCs, than do females, and there is no effect of age on these parameters.</title><p>(<bold>A</bold>) Effect of age (X-axis) on % AREG<sup>+</sup> ILCs or MFI in ILCs (Y-axis as indicated). Each dot represents an individual blood donor, with yellow for female and blue for male. Shading represents the 95% CI. (<bold>B</bold>) Table of results for regression analyses plotted in (<bold>A</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74681-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s3-12"><title>Effect of sex and COVID-19 on fraction of blood ILCs that produce amphiregulin</title><p>Given the role that AREG-producing ILCs play in maintaining disease tolerance in animal models (<xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), sex differences in the functional capability of these ILCs could contribute to the greater risk for severe COVID-19 in males (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>). To address this hypothesis, ILCs isolated from the peripheral blood of controls were stimulated with PMA and ionomycin, and assayed by flow cytometry for AREG production. Consistent with the apparently lower disease tolerance in males, males had a lower median fraction of AREG<sup>+</sup> ILCs than did females (p = 0.018) (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). This difference was also reflected in a significantly lower AREG Mean Fluorescent Intensity (MFI) in males, and neither fraction of AREG<sup>+</sup> ILCs nor AREG MFI was affected by age (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Multiple linear regression was performed, with age, sex, and group as independent variables, to determine whether hospitalization with COVID-19 was associated with differences in the percentage of AREG<sup>+</sup> ILCs. This analysis showed that, after accounting for effects of age and sex, patients hospitalized with COVID-19 had a 1.91-fold lower percentage of AREG<sup>+</sup> ILCs (95% CI: 1.19–3.06; p = 8.06 x 10<sup>–3</sup>) than controls (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>The outcome of SARS-CoV-2 infection ranges from entirely asymptomatic to lethal COVID-19 (<xref ref-type="bibr" rid="bib19">Cevik et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Jones et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Lennon et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Ra et al., 2021</xref>; <xref ref-type="bibr" rid="bib90">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Yang et al., 2021</xref>). Yet, viral load does not reliably discriminate asymptomatic from symptomatic or hospitalized populations (<xref ref-type="bibr" rid="bib19">Cevik et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Jones et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Lennon et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Ra et al., 2021</xref>; <xref ref-type="bibr" rid="bib107">Yang et al., 2021</xref>). In contrast, demographic factors, including increasing age and male sex, predict worse outcome of SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib2">Alkhouli et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Bunders and Altfeld, 2020</xref>; <xref ref-type="bibr" rid="bib39">Gupta et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Laxminarayan et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Mauvais-Jarvis, 2020</xref>; <xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Peckham et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Richardson et al., 2020</xref>; <xref ref-type="bibr" rid="bib95">Scully et al., 2020</xref>). These demographic risk factors could be due to sexual dimorphism and changes with aging in composition and function of the human immune system (<xref ref-type="bibr" rid="bib26">Darboe et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Klein and Flanagan, 2016</xref>; <xref ref-type="bibr" rid="bib71">Márquez et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Patin et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Solana et al., 2012</xref>). Therefore it is necessary to account for effects of age and sex to determine if there are additional, independent, effects of SARS-CoV-2-associated disease.</p><p>This study collected and analyzed 245 blood samples from 177 adult and 58 pediatric patients and controls, spanning the ages of 0.7–83 years, with approximately equal numbers of males and females. It was therefore possible to characterize the independent effects of age, sex, COVID-19, and MIS-C on blood lymphoid cell populations. After accounting for effects of age and sex, ILCs, but not CD4<sup>+</sup> or CD8<sup>+</sup> T cells, were lower in individuals hospitalized with COVID-19 when compared with controls (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3A, B</xref>). Lower numbers of ILCs were also observed in children with COVID-19 (<xref ref-type="table" rid="table5">Table 5</xref> and <xref ref-type="fig" rid="fig4">Figure 4A, B</xref>), as well as in an independent cohort of adult patients (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Among adults infected with SARS-CoV-2, lower abundance of ILCs, but not of the other lymphoid cell subsets, was associated with increased odds of hospitalization, longer duration of hospitalization, and higher blood level of factors associated with systemic inflammation, including CRP (<xref ref-type="table" rid="table3 table4">Tables 3 and 4</xref>, and <xref ref-type="fig" rid="fig3">Figure 3C</xref>). This inverse relationship between ILC abundance and CRP was also evident in children with COVID-19 or MIS-C (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><p>The identification of reduced ILC numbers as uniquely related to COVID-19 severity is important as these cells mediate disease tolerance in animal models (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Califano et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>). The results here therefore indicate that loss of ILCs from blood correlates with loss of ILC-associated homeostatic functions, thereby allowing more severe COVID-19. Although this study examined circulating blood lymphoid cells, and does not provide direct information about processes occurring within tissues, transcriptional and functional characterization of blood ILCs demonstrated that these cells are similar to ILCs isolated from lung tissue (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Human ILCs circulate in lymphatic fluid draining from the tissues to the blood via the thoracic duct (<xref ref-type="bibr" rid="bib15">Buggert et al., 2020</xref>), raising the possibility that some ILCs in the blood originate from, or traffic to, lung tissue. Further characterization of these blood ILCs showed that they are functional ILC2s capable of producing the protein AREG (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Given the tissue homeostatic role AREG plays in animal models of disease tolerance (<xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Jamieson et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), the discovery here that males have a smaller fraction than females of blood ILCs capable of producing AREG (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) could explain why males are at greater risk of death from SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>). This sexual dimorphism in ILC function would be amplified further by the lower overall abundance of ILCs in males (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Although the inverse relationship between the number of blood ILCs and severity of COVID-19 suggests that loss of ILC homeostatic function results in breakdown of disease tolerance (<xref ref-type="bibr" rid="bib5">Arpaia et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), this observational study cannot determine whether ILC depletion preceded SARS-CoV-2 infection or whether ILC numbers are depleted as a consequence of SARS-CoV-2 infection. However, several observations support the hypothesis that individuals with lower ILC numbers at the time of SARS-CoV-2 infection are at greater risk of developing severe disease. ILC numbers in uninfected controls decrease exponentially with age; this decrease is much larger than that seen with other lymphoid cell types (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), and much more closely mirrors the exponential increase in COVID-19 mortality with age (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). In addition, the greater risk of COVID-19 mortality in males (<xref ref-type="bibr" rid="bib79">O’Driscoll et al., 2021</xref>) correlates with lower abundance of blood ILCs (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="table" rid="table2">Table 2</xref>) and smaller fraction of ILCs capable of producing AREG (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Finally, patients hospitalized with COVID-19 have a smaller fraction of AREG<sup>+</sup> ILCs than controls (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) and conditions independently associated with lower ILC abundance, such as HIV-1 infection (<xref ref-type="bibr" rid="bib53">Kløverpris et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Wang et al., 2020</xref>) and obesity (<xref ref-type="bibr" rid="bib14">Brestoff et al., 2015</xref>; <xref ref-type="bibr" rid="bib111">Yudanin et al., 2019</xref>), increase the risk for worse outcomes from SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib11">Biccard et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Kompaniyets et al., 2021</xref>; <xref ref-type="bibr" rid="bib97">Tesoriero et al., 2021</xref>).</p><p>In contrast to individuals with COVID-19, children with MIS-C had lower numbers of T cells as well as ILCs (<xref ref-type="table" rid="table5">Table 5</xref> and <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>), and longitudinal follow-up samples for pediatric COVID-19 and MIS-C patients showed persistence of low ILC numbers after COVID-19, but normalization of all depleted cell types after recovery from MIS-C (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). These differences imply that the reversible lymphopenia in MIS-C is due to different underlying processes than the more specific and persistent lower ILC abundance seen in individuals with COVID-19. This difference is made more interesting by the fact that none of the children with MIS-C had required hospitalization for COVID-19 and only one experienced any COVID-19 symptoms. The other children with MIS-C were therefore unaware that they had been infected. It is possible that children with pre-existing lower ILC numbers are at risk of developing COVID-19 if infected with SARS-CoV-2, while other factors such as prolonged exposure to SARS-CoV-2 antigens in the gastrointestinal tract (<xref ref-type="bibr" rid="bib109">Yonker et al., 2021</xref>), or rare inborn errors of immunity (<xref ref-type="bibr" rid="bib93">Sancho-Shimizu et al., 2021</xref>), promote inflammatory processes in MIS-C that drive nonspecific lymphoid cell depletion, which ultimately normalizes after recovery.</p><p>Although ILC depletion and recovery has been reported in rheumatoid arthritis (<xref ref-type="bibr" rid="bib89">Rauber et al., 2017</xref>), inflammation-driven ILC-depletion is not necessarily reversible, as ILCs appear permanently depleted after HIV-1 infection, possibly by the high levels of common γ-chain cytokines that are present during acute infection (<xref ref-type="bibr" rid="bib101">Wang et al., 2020</xref>). Better understanding of the processes that drive down ILC abundance in populations susceptible to COVID-19 could potentially allow for development of interventions that increase ILC abundance and restore homeostatic disease tolerance mechanisms.</p><p>In conclusion, considering the established functions of ILCs (<xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Klose and Artis, 2016</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), and the host homeostatic responses necessary to survive pathogenic infection (<xref ref-type="bibr" rid="bib65">López-Otín and Kroemer, 2021</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib75">Medzhitov et al., 2012</xref>; <xref ref-type="bibr" rid="bib94">Schneider and Ayres, 2008</xref>), the findings reported here support the hypothesis that loss of disease tolerance mechanisms attributable to ILCs increase the risk of morbidity and mortality with SARS-CoV-2 infection. The findings of this observational study warrant establishment of prospective cohorts to determine whether abundance of ILCs or of other lymphoid cell subsets associated with disease tolerance (<xref ref-type="bibr" rid="bib5">Arpaia et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Artis and Spits, 2015</xref>; <xref ref-type="bibr" rid="bib13">Branzk et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Diefenbach et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McCarville and Ayres, 2018</xref>; <xref ref-type="bibr" rid="bib77">Monticelli et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Monticelli et al., 2011</xref>), predict clinical outcome for infection with SARS-CoV-2 or other lethal pathogens. Understanding the mechanisms that allow an individual to tolerate high-level viral replication without experiencing symptoms, and how these mechanisms can fail and thereby allow for progression to severe disease, will provide the foundation for development of therapeutic interventions that maintain health and improve survival of pathogenic viral infection (<xref ref-type="bibr" rid="bib8">Ayres, 2020b</xref>).</p></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Software, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con10"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Data curation, Resources</p></fn><fn fn-type="con" id="con13"><p>Data curation, Resources</p></fn><fn fn-type="con" id="con14"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Data curation, Investigation, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Data curation, Funding acquisition, Investigation, Resources, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: As part of a COVID-19 observational study, peripheral blood samples were collected between March 31st and June 3rd of 2020 from 91 adults with SARS-CoV-2 infection, either after admission to Massachusetts General Hospital for the hospitalized cohort, or while at affiliated outpatient clinics for the outpatient cohort. Request for access to coded patient samples was reviewed by the Massachusetts Consortium for Pathogen Readiness (https://masscpr.hms.harvard.edu/) and approved by the University of Massachusetts Medical School IRB (protocol #H00020836). Pediatric participants with COVID-19 or MIS-C were enrolled in the Massachusetts General Hospital Pediatric COVID-19 Biorepository (MGB IRB # 2020P000955). Healthy pediatric controls were enrolled in the Pediatric Biorepository (MGB IRB # 2016P000949). Samples were collected after obtaining consent from the patient if 18 years or older, or from the parent/guardian, plus assent when appropriate.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Antibodies and sequencing primers used here.</title><p>(<bold>a</bold>) Antibodies Used in Flow Cytometry. (b) Primers for bulk RNA-Seq.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74681-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Supplementary Tables.</title><p>(<bold>a</bold>) Race and Ethnicity of Adult Cohorts (b) Demographic and Clinical Characteristics of Pediatric Blood Donor Groups (c) Comparison of sex ratios between control age groups (d) Change in Lymphocyte Abundance Per 10<sup>6</sup> PBMCs Due to Age, Sex, and COVID-19 Severity in Adult cohorts (e) Change in Lymphoid Cell Abundance Per 10<sup>6</sup> PBMCs Due to Age, Sex, and COVID-19 Severity (f) Odds of Hospitalization in Pediatric Cohort (g) Change in Pediatric Cohort Lymphoid Cell Abundance Per 10<sup>6</sup> lymphocytes due to Group; Adjusted for Effects of Age and Sex with Combined Pediatric and Adult Control Data (h) Gene ontology analysis results.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74681-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-74681-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available within the manuscript and in its supplementary information data files. Bulk RNA-Seq datasets generated here can be found at: NCBI Gene Expression Omnibus (GEO): GSE168212. Bulk RNA-Seq data generated by previously published studies are available from NCBI GEO: GSE131031 and GSE126107. This study did not generate unique code.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lifshitz</surname><given-names>LM</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Systematic analysis of innate lymphoid cells and natural killer cells in context of HIV-1 infection</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168212">GSE168212</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Khader</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Group 3 innate lymphoid cells mediate early protective immunity against Mycobacterium tuberculosis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131031">GSE131031</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Yudanin</surname><given-names>N</given-names></name><name><surname>Latorre</surname><given-names>I</given-names></name><name><surname>Covington</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126107">GSE126107</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Massachusetts Consortium for Pathogen Readiness Specimen Collection and Processing Team listed below and members of the Yu and Luban Labs. This work was supported in part by the Massachusetts Consortium for Pathogen Readiness and NIH grants R37AI147868 and R01AI148784 to JL and Ruth L Kirschstein NRSA Fellowship F30HD100110 to NJS. The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon Institute of MGH, MIT and Harvard. The Pediatric COVID-19 Biorepository was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), and the Department of Pediatrics at Massachusetts General Hospital <italic>for</italic> Children (to LMY).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alghamdi</surname><given-names>IG</given-names></name><name><surname>Hussain</surname><given-names>II</given-names></name><name><surname>Almalki</surname><given-names>SS</given-names></name><name><surname>Alghamdi</surname><given-names>MS</given-names></name><name><surname>Alghamdi</surname><given-names>MM</given-names></name><name><surname>El-Sheemy</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health</article-title><source>International Journal of General Medicine</source><volume>7</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S67061</pub-id><pub-id pub-id-type="pmid">25187734</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhouli</surname><given-names>M</given-names></name><name><surname>Nanjundappa</surname><given-names>A</given-names></name><name><surname>Annie</surname><given-names>F</given-names></name><name><surname>Bates</surname><given-names>MC</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry</article-title><source>Mayo Clinic Proceedings</source><volume>95</volume><fpage>1613</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.05.014</pub-id><pub-id pub-id-type="pmid">32753136</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anegón</surname><given-names>I</given-names></name><name><surname>Cuturi</surname><given-names>MC</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Perussia</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells</article-title><source>The Journal of Experimental Medicine</source><volume>167</volume><fpage>452</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1084/jem.167.2.452</pub-id><pub-id pub-id-type="pmid">2831292</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardain</surname><given-names>A</given-names></name><name><surname>Domingo-Gonzalez</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Kazer</surname><given-names>SW</given-names></name><name><surname>Howard</surname><given-names>NC</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Nhamoyebonde</surname><given-names>S</given-names></name><name><surname>Rangel-Moreno</surname><given-names>J</given-names></name><name><surname>Ogongo</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Ramsuran</surname><given-names>D</given-names></name><name><surname>de la Luz Garcia-Hernandez</surname><given-names>M</given-names></name><name><surname>K Ulland</surname><given-names>T</given-names></name><name><surname>Darby</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Karim</surname><given-names>F</given-names></name><name><surname>Melocchi</surname><given-names>L</given-names></name><name><surname>Madansein</surname><given-names>R</given-names></name><name><surname>Dullabh</surname><given-names>KJ</given-names></name><name><surname>Dunlap</surname><given-names>M</given-names></name><name><surname>Marin-Agudelo</surname><given-names>N</given-names></name><name><surname>Ebihara</surname><given-names>T</given-names></name><name><surname>Ndung’u</surname><given-names>T</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name><name><surname>Pym</surname><given-names>AS</given-names></name><name><surname>Kolls</surname><given-names>JK</given-names></name><name><surname>Steyn</surname><given-names>A</given-names></name><name><surname>Zúñiga</surname><given-names>J</given-names></name><name><surname>Horsnell</surname><given-names>W</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Kløverpris</surname><given-names>HN</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis</article-title><source>Nature</source><volume>570</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1276-2</pub-id><pub-id pub-id-type="pmid">31168092</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arpaia</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Arvey</surname><given-names>A</given-names></name><name><surname>Hemmers</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Treuting</surname><given-names>PM</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A Distinct Function of Regulatory T Cells in Tissue Protection</article-title><source>Cell</source><volume>162</volume><fpage>1078</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.021</pub-id><pub-id pub-id-type="pmid">26317471</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The biology of innate lymphoid cells</article-title><source>Nature</source><volume>517</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/nature14189</pub-id><pub-id pub-id-type="pmid">25592534</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayres</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Surviving COVID-19: A disease tolerance perspective</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eabc1518</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abc1518</pub-id><pub-id pub-id-type="pmid">32494691</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayres</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>The Biology of Physiological Health</article-title><source>Cell</source><volume>181</volume><fpage>250</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.036</pub-id><pub-id pub-id-type="pmid">32302569</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>LC</given-names></name><name><surname>Razzaghi</surname><given-names>H</given-names></name><name><surname>Burrows</surname><given-names>EK</given-names></name><name><surname>Bunnell</surname><given-names>HT</given-names></name><name><surname>Camacho</surname><given-names>PEF</given-names></name><name><surname>Christakis</surname><given-names>DA</given-names></name><name><surname>Eckrich</surname><given-names>D</given-names></name><name><surname>Kitzmiller</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>SM</given-names></name><name><surname>Magnusen</surname><given-names>BC</given-names></name><name><surname>Newland</surname><given-names>J</given-names></name><name><surname>Pajor</surname><given-names>NM</given-names></name><name><surname>Ranade</surname><given-names>D</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Sofela</surname><given-names>O</given-names></name><name><surname>Zahner</surname><given-names>J</given-names></name><name><surname>Bruno</surname><given-names>C</given-names></name><name><surname>Forrest</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States</article-title><source>JAMA Pediatrics</source><volume>175</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.5052</pub-id><pub-id pub-id-type="pmid">33226415</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Mächler</surname><given-names>M</given-names></name><name><surname>Bolker</surname><given-names>B</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fitting Linear Mixed-Effects Models Usinglme4</article-title><source>Journal of Statistical Software</source><volume>67</volume><pub-id pub-id-type="doi">10.18637/jss.v067.i01</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biccard</surname><given-names>BM</given-names></name><name><surname>Gopalan</surname><given-names>PD</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Michell</surname><given-names>WL</given-names></name><name><surname>Thomson</surname><given-names>D</given-names></name><name><surname>Ademuyiwa</surname><given-names>A</given-names></name><name><surname>Aniteye</surname><given-names>E</given-names></name><name><surname>Calligaro</surname><given-names>G</given-names></name><name><surname>Chaibou</surname><given-names>MS</given-names></name><name><surname>Dhufera</surname><given-names>HT</given-names></name><name><surname>Elfagieh</surname><given-names>M</given-names></name><name><surname>Elfiky</surname><given-names>M</given-names></name><name><surname>Elhadi</surname><given-names>M</given-names></name><name><surname>Fawzy</surname><given-names>M</given-names></name><name><surname>Fredericks</surname><given-names>D</given-names></name><name><surname>Gebre</surname><given-names>M</given-names></name><name><surname>Bayih</surname><given-names>AG</given-names></name><name><surname>Hardy</surname><given-names>A</given-names></name><name><surname>Joubert</surname><given-names>I</given-names></name><name><surname>Kifle</surname><given-names>F</given-names></name><name><surname>Kluyts</surname><given-names>HL</given-names></name><name><surname>Macleod</surname><given-names>K</given-names></name><name><surname>Mekonnen</surname><given-names>Z</given-names></name><name><surname>Mer</surname><given-names>M</given-names></name><name><surname>Morais</surname><given-names>A</given-names></name><name><surname>Msosa</surname><given-names>V</given-names></name><name><surname>Mulwafu</surname><given-names>W</given-names></name><name><surname>Ndonga</surname><given-names>A</given-names></name><name><surname>Ngumi</surname><given-names>Z</given-names></name><name><surname>Omigbodun</surname><given-names>A</given-names></name><name><surname>Owoo</surname><given-names>C</given-names></name><name><surname>Paruk</surname><given-names>F</given-names></name><name><surname>Piercy</surname><given-names>JL</given-names></name><name><surname>Scribante</surname><given-names>J</given-names></name><name><surname>Seman</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Straaten</surname><given-names>D</given-names></name><name><surname>Elfiky</surname><given-names>M</given-names></name><name><surname>Fawzy</surname><given-names>M</given-names></name><name><surname>Awad</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>H</given-names></name><name><surname>Shaban</surname><given-names>M</given-names></name><name><surname>Elbadawy</surname><given-names>M</given-names></name><name><surname>Elmehrath</surname><given-names>AO</given-names></name><name><surname>Cordie</surname><given-names>A</given-names></name><name><surname>Elganainy</surname><given-names>M</given-names></name><name><surname>El-Shazly</surname><given-names>M</given-names></name><name><surname>Essam</surname><given-names>M</given-names></name><name><surname>Abdelwahab</surname><given-names>OA</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>AM</given-names></name><name><surname>Kamel</surname><given-names>EZ</given-names></name><name><surname>Monib</surname><given-names>FA</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Saad</surname><given-names>MM</given-names></name><name><surname>Al-Quossi</surname><given-names>MA</given-names></name><name><surname>Rafaat</surname><given-names>N</given-names></name><name><surname>Galal</surname><given-names>I</given-names></name><name><surname>Labib</surname><given-names>B</given-names></name><name><surname>Omran</surname><given-names>DO</given-names></name><name><surname>Fawzy</surname><given-names>M</given-names></name><name><surname>Elfiky</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Azab</surname><given-names>M</given-names></name><name><surname>Tawheed</surname><given-names>A</given-names></name><name><surname>Gamal</surname><given-names>M</given-names></name><name><surname>El Kassas</surname><given-names>M</given-names></name><name><surname>Aml</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>NasrEldin</surname><given-names>Y</given-names></name><name><surname>Abdewahab</surname><given-names>O</given-names></name><name><surname>Elganainy</surname><given-names>M</given-names></name><name><surname>Elmandouh</surname><given-names>O</given-names></name><name><surname>Dhufera</surname><given-names>HT</given-names></name><name><surname>MeGebre</surname><given-names>M</given-names></name><name><surname>Bayih</surname><given-names>AG</given-names></name><name><surname>Kifle</surname><given-names>F</given-names></name><name><surname>Mekonnen</surname><given-names>Z</given-names></name><name><surname>Seman</surname><given-names>Y</given-names></name><name><surname>Addisie</surname><given-names>A</given-names></name><name><surname>Eshete</surname><given-names>A</given-names></name><name><surname>Kifle</surname><given-names>F</given-names></name><name><surname>Desita</surname><given-names>K</given-names></name><name><surname>Araya</surname><given-names>H</given-names></name><name><surname>Agidew</surname><given-names>Y</given-names></name><name><surname>Andabo</surname><given-names>AD</given-names></name><name><surname>Tesfaye</surname><given-names>E</given-names></name><name><surname>Yesuf</surname><given-names>EA</given-names></name><name><surname>Hailemariam</surname><given-names>G</given-names></name><name><surname>Mohammed</surname><given-names>MS</given-names></name><name><surname>Gebremedhin</surname><given-names>Y</given-names></name><name><surname>Taye</surname><given-names>Y</given-names></name><name><surname>Mebrate</surname><given-names>TA</given-names></name><name><surname>Gemechu</surname><given-names>TB</given-names></name><name><surname>Bedane</surname><given-names>TT</given-names></name><name><surname>Abera</surname><given-names>ET</given-names></name><name><surname>Teshome</surname><given-names>A</given-names></name><name><surname>Ernest Aniteye</surname><given-names>EA</given-names></name><name><surname>Christian Owoo</surname><given-names>CO</given-names></name><name><surname>Doku</surname><given-names>A</given-names></name><name><surname>Afriyie-Mensah</surname><given-names>JS</given-names></name><name><surname>Lawson</surname><given-names>A</given-names></name><name><surname>DYaw Sottie</surname><given-names>DA</given-names></name><name><surname>Addae</surname><given-names>E</given-names></name><name><surname>Ernest Ofosu-Appiah</surname><given-names>EOA</given-names></name><name><surname>William Obeng</surname><given-names>WO</given-names></name><name><surname>Ndonga</surname><given-names>A</given-names></name><name><surname>Ngumi</surname><given-names>Z</given-names></name><name><surname>Ndonga</surname><given-names>A</given-names></name><name><surname>Mugera</surname><given-names>A</given-names></name><name><surname>Bitta</surname><given-names>C</given-names></name><name><surname>Elfagieh</surname><given-names>M</given-names></name><name><surname>Elhadi</surname><given-names>M</given-names></name><name><surname>Huwaysh</surname><given-names>MA</given-names></name><name><surname>Yahya</surname><given-names>MMA</given-names></name><name><surname>Mohammed</surname><given-names>AAK</given-names></name><name><surname>Majeed</surname><given-names>AAM</given-names></name><name><surname>Mohammed</surname><given-names>AEM</given-names></name><name><surname>Majeed</surname><given-names>E</given-names></name><name><surname>Abusalama</surname><given-names>AA</given-names></name><name><surname>Altayr</surname><given-names>E</given-names></name><name><surname>Abubaker</surname><given-names>T</given-names></name><name><surname>Alkaseek</surname><given-names>AM</given-names></name><name><surname>Abdulhafith</surname><given-names>B</given-names></name><name><surname>Alziyituni</surname><given-names>Z</given-names></name><name><surname>Gamra</surname><given-names>MF</given-names></name><name><surname>Anaiba</surname><given-names>MM</given-names></name><name><surname>Khel</surname><given-names>S</given-names></name><name><surname>Abdelkabir</surname><given-names>M</given-names></name><name><surname>Abdeewi</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>S</given-names></name><name><surname>Alhadi</surname><given-names>A</given-names></name><name><surname>Alsoufi</surname><given-names>A</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Msherghi</surname><given-names>A</given-names></name><name><surname>Bouhuwaish</surname><given-names>AEM</given-names></name><name><surname>Msosa</surname><given-names>V</given-names></name><name><surname>Mulwafu</surname><given-names>W</given-names></name><name><surname>Masoo</surname><given-names>F</given-names></name><name><surname>Chikumbanje</surname><given-names>SS</given-names></name><name><surname>Mabedi</surname><given-names>D</given-names></name><name><surname>Morais</surname><given-names>A</given-names></name><name><surname>Carlos</surname><given-names>A</given-names></name><name><surname>Morais</surname><given-names>A</given-names></name><name><surname>Lorenzoni</surname><given-names>C</given-names></name><name><surname>Mambo</surname><given-names>J</given-names></name><name><surname>Isabel Chissaque</surname><given-names>I</given-names></name><name><surname>Mouzinho Saide</surname><given-names>M</given-names></name><name><surname>Chaibou</surname><given-names>MS</given-names></name><name><surname>Mamane</surname><given-names>M</given-names></name><name><surname>Amadou</surname><given-names>F</given-names></name><name><surname>Adesoji Ademuyiwa</surname><given-names>AA</given-names></name><name><surname>Akinyinka Omigbodun</surname><given-names>AO</given-names></name><name><surname>Adeyeye</surname><given-names>A</given-names></name><name><surname>Akinmade</surname><given-names>A</given-names></name><name><surname>Momohsani</surname><given-names>Y</given-names></name><name><surname>Bamigboye</surname><given-names>J</given-names></name><name><surname>Orshio</surname><given-names>D</given-names></name><name><surname>Isamade</surname><given-names>ES</given-names></name><name><surname>Embu</surname><given-names>H</given-names></name><name><surname>Nuhu</surname><given-names>S</given-names></name><name><surname>Ojiakor</surname><given-names>S</given-names></name><name><surname>Nuhu</surname><given-names>A</given-names></name><name><surname>Fowotade</surname><given-names>A</given-names></name><name><surname>Sanusi</surname><given-names>A</given-names></name><name><surname>Osinaike</surname><given-names>B</given-names></name><name><surname>Idowu</surname><given-names>O</given-names></name><name><surname>Amali</surname><given-names>AO</given-names></name><name><surname>Ibrahim</surname><given-names>S</given-names></name><name><surname>Adamu</surname><given-names>AA</given-names></name><name><surname>Kida</surname><given-names>I</given-names></name><name><surname>Otokwala</surname><given-names>J</given-names></name><name><surname>Essam</surname><given-names>M</given-names></name><name><surname>Alagbe-Briggs</surname><given-names>O</given-names></name><name><surname>Ojum</surname><given-names>S</given-names></name><name><surname>Fathima Paruk</surname><given-names>FP</given-names></name><name><surname>Juan Scribante</surname><given-names>JS</given-names></name><name><surname>Mdladla</surname><given-names>A</given-names></name><name><surname>Mabotja</surname><given-names>T</given-names></name><name><surname>Naidoo</surname><given-names>R</given-names></name><name><surname>Matos-Puig</surname><given-names>R</given-names></name><name><surname>Ramkillawan</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Arnold-Day</surname><given-names>C</given-names></name><name><surname>Thomson</surname><given-names>D</given-names></name><name><surname>Calligaro</surname><given-names>G</given-names></name><name><surname>Joubert</surname><given-names>I</given-names></name><name><surname>Jagga</surname><given-names>J</given-names></name><name><surname>Piercy</surname><given-names>J</given-names></name><name><surname>Michell</surname><given-names>L</given-names></name><name><surname>Devenish</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Fernandes</surname><given-names>N</given-names></name><name><surname>Gopalan</surname><given-names>D</given-names></name><name><surname>Pershad</surname><given-names>S</given-names></name><name><surname>Grabowski</surname><given-names>N</given-names></name><name><surname>Rammego</surname><given-names>M</given-names></name><name><surname>Zwane</surname><given-names>S</given-names></name><name><surname>Dhlamini</surname><given-names>ME</given-names></name><name><surname>Neuhoff</surname><given-names>M</given-names></name><name><surname>Fodo</surname><given-names>T</given-names></name><name><surname>Usenbo</surname><given-names>A</given-names></name><name><surname>Mrara</surname><given-names>B</given-names></name><name><surname>Kabambi</surname><given-names>F</given-names></name><name><surname>Cloete</surname><given-names>E</given-names></name><name><surname>De Caires</surname><given-names>L</given-names></name><name><surname>Dickerson</surname><given-names>R</given-names></name><name><surname>Louw</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study</article-title><source>Lancet (London, England)</source><volume>397</volume><fpage>1885</fpage><lpage>1894</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00441-4</pub-id><pub-id pub-id-type="pmid">34022988</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>B</given-names></name><name><surname>Cosme</surname><given-names>J</given-names></name><name><surname>Dupuis</surname><given-names>C</given-names></name><name><surname>Coupez</surname><given-names>E</given-names></name><name><surname>Adda</surname><given-names>M</given-names></name><name><surname>Calvet</surname><given-names>L</given-names></name><name><surname>Fabre</surname><given-names>L</given-names></name><name><surname>Saint-Sardos</surname><given-names>P</given-names></name><name><surname>Bereiziat</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Laurichesse</surname><given-names>H</given-names></name><name><surname>Souweine</surname><given-names>B</given-names></name><name><surname>Evrard</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation</article-title><source>EBioMedicine</source><volume>73</volume><elocation-id>103622</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103622</pub-id><pub-id pub-id-type="pmid">34678611</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branzk</surname><given-names>N</given-names></name><name><surname>Gronke</surname><given-names>K</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate lymphoid cells, mediators of tissue homeostasis, adaptation and disease tolerance</article-title><source>Immunological Reviews</source><volume>286</volume><fpage>86</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/imr.12718</pub-id><pub-id pub-id-type="pmid">30294961</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brestoff</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Saenz</surname><given-names>SA</given-names></name><name><surname>Stine</surname><given-names>RR</given-names></name><name><surname>Monticelli</surname><given-names>LA</given-names></name><name><surname>Sonnenberg</surname><given-names>GF</given-names></name><name><surname>Thome</surname><given-names>JJ</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name><name><surname>Lutfy</surname><given-names>K</given-names></name><name><surname>Seale</surname><given-names>P</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity</article-title><source>Nature</source><volume>519</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/nature14115</pub-id><pub-id pub-id-type="pmid">25533952</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>VH</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Perez-Potti</surname><given-names>A</given-names></name><name><surname>Maldini</surname><given-names>CR</given-names></name><name><surname>Manne</surname><given-names>S</given-names></name><name><surname>Darko</surname><given-names>S</given-names></name><name><surname>Ransier</surname><given-names>A</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Japp</surname><given-names>AS</given-names></name><name><surname>Brody</surname><given-names>IB</given-names></name><name><surname>Ivarsson</surname><given-names>MA</given-names></name><name><surname>Gorin</surname><given-names>JB</given-names></name><name><surname>Rivera-Ballesteros</surname><given-names>O</given-names></name><name><surname>Hertwig</surname><given-names>L</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Johnson</surname><given-names>ME</given-names></name><name><surname>Okoye</surname><given-names>A</given-names></name><name><surname>Picker</surname><given-names>L</given-names></name><name><surname>Vahedi</surname><given-names>G</given-names></name><name><surname>Sparrelid</surname><given-names>E</given-names></name><name><surname>Llewellyn-Lacey</surname><given-names>S</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Björkström</surname><given-names>N</given-names></name><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Dori</surname><given-names>Y</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Canaday</surname><given-names>DH</given-names></name><name><surname>Laufer</surname><given-names>TM</given-names></name><name><surname>Wells</surname><given-names>AD</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Frank</surname><given-names>I</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Itkin</surname><given-names>MG</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Identity of Human Tissue-Emigrant CD8+ T Cells</article-title><source>Cell</source><volume>183</volume><fpage>1946</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.019</pub-id><pub-id pub-id-type="pmid">33306960</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunders</surname><given-names>MJ</given-names></name><name><surname>Altfeld</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions</article-title><source>Immunity</source><volume>53</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.08.003</pub-id><pub-id pub-id-type="pmid">32853545</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Califano</surname><given-names>D</given-names></name><name><surname>Furuya</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Avram</surname><given-names>D</given-names></name><name><surname>McKenzie</surname><given-names>ANJ</given-names></name><name><surname>Metzger</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IFN-γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells</article-title><source>Mucosal Immunology</source><volume>11</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.41</pub-id><pub-id pub-id-type="pmid">28513592</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="web"><person-group person-group-type="author"><collab>CDC Case Surveillance Task Force</collab></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 Case Surveillance Public Use Data</article-title><source>Centers for Disease Control and Prevention</source><ext-link ext-link-type="uri" xlink:href="https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data/vbim-akqf">https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data/vbim-akqf</ext-link><date-in-citation iso-8601-date="2021-06-25">June 25, 2021</date-in-citation></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>M</given-names></name><name><surname>Tate</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>O</given-names></name><name><surname>Maraolo</surname><given-names>AE</given-names></name><name><surname>Schafers</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis</article-title><source>The Lancet. Microbe</source><volume>2</volume><fpage>e13</fpage><lpage>e22</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(20)30172-5</pub-id><pub-id pub-id-type="pmid">33521734</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fett</surname><given-names>C</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Ten Eyck</surname><given-names>PP</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>4046</fpage><lpage>4053</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601896</pub-id><pub-id pub-id-type="pmid">28373583</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Immunobiology of SARS</article-title><source>Annual Review of Immunology</source><volume>25</volume><fpage>443</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.25.022106.141706</pub-id><pub-id pub-id-type="pmid">17243893</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>2620</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><pub-id pub-id-type="pmid">32217835</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherrier</surname><given-names>DE</given-names></name><name><surname>Serafini</surname><given-names>N</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate Lymphoid Cell Development: A T Cell Perspective</article-title><source>Immunity</source><volume>48</volume><fpage>1091</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.05.010</pub-id><pub-id pub-id-type="pmid">29924975</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>EW</given-names></name><name><surname>Zachariah</surname><given-names>P</given-names></name><name><surname>Gorelik</surname><given-names>M</given-names></name><name><surname>Boneparth</surname><given-names>A</given-names></name><name><surname>Kernie</surname><given-names>SG</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City</article-title><source>JAMA</source><volume>324</volume><fpage>294</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.10374</pub-id><pub-id pub-id-type="pmid">32511676</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumnock</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>AS</given-names></name><name><surname>Lissner</surname><given-names>M</given-names></name><name><surname>Chevee</surname><given-names>V</given-names></name><name><surname>Davis</surname><given-names>NM</given-names></name><name><surname>Schneider</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Host Energy Source Is Important for Disease Tolerance to Malaria</article-title><source>Current Biology</source><volume>28</volume><fpage>1635</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2018.04.009</pub-id><pub-id pub-id-type="pmid">29754902</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darboe</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>CM</given-names></name><name><surname>Wolf</surname><given-names>AS</given-names></name><name><surname>Wildfire</surname><given-names>J</given-names></name><name><surname>Danso</surname><given-names>E</given-names></name><name><surname>Sonko</surname><given-names>B</given-names></name><name><surname>Bottomley</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>SE</given-names></name><name><surname>Riley</surname><given-names>EM</given-names></name><name><surname>Goodier</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Age-Related Dynamics of Circulating Innate Lymphoid Cells in an African Population</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>594107</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.594107</pub-id><pub-id pub-id-type="pmid">33343571</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diefenbach</surname><given-names>A</given-names></name><name><surname>Gnafakis</surname><given-names>S</given-names></name><name><surname>Shomrat</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate Lymphoid Cell-Epithelial Cell Modules Sustain Intestinal Homeostasis</article-title><source>Immunity</source><volume>52</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.02.016</pub-id><pub-id pub-id-type="pmid">32187516</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics (Oxford, England)</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>CA</given-names></name><name><surname>Ghani</surname><given-names>AC</given-names></name><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Hedley</surname><given-names>AJ</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name><name><surname>Riley</surname><given-names>S</given-names></name><name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name><name><surname>Ho</surname><given-names>LM</given-names></name><name><surname>Thach</surname><given-names>TQ</given-names></name><name><surname>Chau</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>KP</given-names></name><name><surname>Lam</surname><given-names>TH</given-names></name><name><surname>Tse</surname><given-names>LY</given-names></name><name><surname>Tsang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Kong</surname><given-names>JHB</given-names></name><name><surname>Lau</surname><given-names>EMC</given-names></name><name><surname>Ferguson</surname><given-names>NM</given-names></name><name><surname>Anderson</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong</article-title><source>Lancet (London, England)</source><volume>361</volume><fpage>1761</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13410-1</pub-id><pub-id pub-id-type="pmid">12781533</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Souza</surname><given-names>SS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Fung</surname><given-names>ITH</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Kuentzel</surname><given-names>M</given-names></name><name><surname>Chittur</surname><given-names>SV</given-names></name><name><surname>Furuya</surname><given-names>Y</given-names></name><name><surname>Siebel</surname><given-names>CW</given-names></name><name><surname>Maillard</surname><given-names>IP</given-names></name><name><surname>Metzger</surname><given-names>DW</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Compartmentalized effects of aging on group 2 innate lymphoid cell development and function</article-title><source>Aging Cell</source><volume>18</volume><elocation-id>e13019</elocation-id><pub-id pub-id-type="doi">10.1111/acel.13019</pub-id><pub-id pub-id-type="pmid">31429526</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldstein</surname><given-names>LR</given-names></name><name><surname>Rose</surname><given-names>EB</given-names></name><name><surname>Horwitz</surname><given-names>SM</given-names></name><name><surname>Collins</surname><given-names>JP</given-names></name><name><surname>Newhams</surname><given-names>MM</given-names></name><name><surname>Son</surname><given-names>MBF</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Kleinman</surname><given-names>LC</given-names></name><name><surname>Heidemann</surname><given-names>SM</given-names></name><name><surname>Martin</surname><given-names>AA</given-names></name><name><surname>Singh</surname><given-names>AR</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tarquinio</surname><given-names>KM</given-names></name><name><surname>Jaggi</surname><given-names>P</given-names></name><name><surname>Oster</surname><given-names>ME</given-names></name><name><surname>Zackai</surname><given-names>SP</given-names></name><name><surname>Gillen</surname><given-names>J</given-names></name><name><surname>Ratner</surname><given-names>AJ</given-names></name><name><surname>Walsh</surname><given-names>RF</given-names></name><name><surname>Fitzgerald</surname><given-names>JC</given-names></name><name><surname>Keenaghan</surname><given-names>MA</given-names></name><name><surname>Alharash</surname><given-names>H</given-names></name><name><surname>Doymaz</surname><given-names>S</given-names></name><name><surname>Clouser</surname><given-names>KN</given-names></name><name><surname>Giuliano</surname><given-names>JS</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>RM</given-names></name><name><surname>Maddux</surname><given-names>AB</given-names></name><name><surname>Havalad</surname><given-names>V</given-names></name><name><surname>Ramsingh</surname><given-names>S</given-names></name><name><surname>Bukulmez</surname><given-names>H</given-names></name><name><surname>Bradford</surname><given-names>TT</given-names></name><name><surname>Smith</surname><given-names>LS</given-names></name><name><surname>Tenforde</surname><given-names>MW</given-names></name><name><surname>Carroll</surname><given-names>CL</given-names></name><name><surname>Riggs</surname><given-names>BJ</given-names></name><name><surname>Gertz</surname><given-names>SJ</given-names></name><name><surname>Daube</surname><given-names>A</given-names></name><name><surname>Lansell</surname><given-names>A</given-names></name><name><surname>Coronado Munoz</surname><given-names>A</given-names></name><name><surname>Hobbs</surname><given-names>CV</given-names></name><name><surname>Marohn</surname><given-names>KL</given-names></name><name><surname>Halasa</surname><given-names>NB</given-names></name><name><surname>Patel</surname><given-names>MM</given-names></name><name><surname>Randolph</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. 2020. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents</article-title><source>The New England Journal of Medicine</source><volume>383</volume><elocation-id>NEJMoa2021680</elocation-id><pub-id pub-id-type="doi">10.1056/NEJMoa2021680</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldstein</surname><given-names>LR</given-names></name><name><surname>Tenforde</surname><given-names>MW</given-names></name><name><surname>Friedman</surname><given-names>KG</given-names></name><name><surname>Newhams</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>EB</given-names></name><name><surname>Dapul</surname><given-names>H</given-names></name><name><surname>Soma</surname><given-names>VL</given-names></name><name><surname>Maddux</surname><given-names>AB</given-names></name><name><surname>Mourani</surname><given-names>PM</given-names></name><name><surname>Bowens</surname><given-names>C</given-names></name><name><surname>Maamari</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>MW</given-names></name><name><surname>Riggs</surname><given-names>BJ</given-names></name><name><surname>Giuliano</surname><given-names>JS</given-names></name><name><surname>Singh</surname><given-names>AR</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>JE</given-names></name><name><surname>McLaughlin</surname><given-names>GE</given-names></name><name><surname>Schwartz</surname><given-names>SP</given-names></name><name><surname>Walker</surname><given-names>TC</given-names></name><name><surname>Loftis</surname><given-names>LL</given-names></name><name><surname>Hobbs</surname><given-names>CV</given-names></name><name><surname>Halasa</surname><given-names>NB</given-names></name><name><surname>Doymaz</surname><given-names>S</given-names></name><name><surname>Babbitt</surname><given-names>CJ</given-names></name><name><surname>Hume</surname><given-names>JR</given-names></name><name><surname>Gertz</surname><given-names>SJ</given-names></name><name><surname>Irby</surname><given-names>K</given-names></name><name><surname>Clouser</surname><given-names>KN</given-names></name><name><surname>Cvijanovich</surname><given-names>NZ</given-names></name><name><surname>Bradford</surname><given-names>TT</given-names></name><name><surname>Smith</surname><given-names>LS</given-names></name><name><surname>Heidemann</surname><given-names>SM</given-names></name><name><surname>Zackai</surname><given-names>SP</given-names></name><name><surname>Wellnitz</surname><given-names>K</given-names></name><name><surname>Nofziger</surname><given-names>RA</given-names></name><name><surname>Horwitz</surname><given-names>SM</given-names></name><name><surname>Carroll</surname><given-names>RW</given-names></name><name><surname>Rowan</surname><given-names>CM</given-names></name><name><surname>Tarquinio</surname><given-names>KM</given-names></name><name><surname>Mack</surname><given-names>EH</given-names></name><name><surname>Fitzgerald</surname><given-names>JC</given-names></name><name><surname>Coates</surname><given-names>BM</given-names></name><name><surname>Jackson</surname><given-names>AM</given-names></name><name><surname>Young</surname><given-names>CC</given-names></name><name><surname>Son</surname><given-names>MBF</given-names></name><name><surname>Patel</surname><given-names>MM</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Randolph</surname><given-names>AG</given-names></name><collab>Overcoming COVID-19 Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19</article-title><source>JAMA</source><volume>325</volume><fpage>1074</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.2091</pub-id><pub-id pub-id-type="pmid">33625505</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>KL</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name><name><surname>Plebanski</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sex and Gender Differences in the Outcomes of Vaccination over the Life Course</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>33</volume><fpage>577</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-100616-060718</pub-id><pub-id pub-id-type="pmid">28992436</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo Marin</surname><given-names>B</given-names></name><name><surname>Aghagoli</surname><given-names>G</given-names></name><name><surname>Lavine</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Siff</surname><given-names>EJ</given-names></name><name><surname>Chiang</surname><given-names>SS</given-names></name><name><surname>Salazar-Mather</surname><given-names>TP</given-names></name><name><surname>Dumenco</surname><given-names>L</given-names></name><name><surname>Savaria</surname><given-names>MC</given-names></name><name><surname>Aung</surname><given-names>SN</given-names></name><name><surname>Flanigan</surname><given-names>T</given-names></name><name><surname>Michelow</surname><given-names>IC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predictors of COVID-19 severity: A literature review</article-title><source>Reviews in Medical Virology</source><volume>31</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/rmv.2146</pub-id><pub-id pub-id-type="pmid">32845042</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García</surname><given-names>M</given-names></name><name><surname>Kokkinou</surname><given-names>E</given-names></name><name><surname>Carrasco García</surname><given-names>A</given-names></name><name><surname>Parrot</surname><given-names>T</given-names></name><name><surname>Palma Medina</surname><given-names>LM</given-names></name><name><surname>Maleki</surname><given-names>KT</given-names></name><name><surname>Christ</surname><given-names>W</given-names></name><name><surname>Varnaitė</surname><given-names>R</given-names></name><name><surname>Filipovic</surname><given-names>I</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name><name><surname>Björkström</surname><given-names>NK</given-names></name><name><surname>Folkesson</surname><given-names>E</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name><name><surname>Eriksson</surname><given-names>LI</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Aleman</surname><given-names>S</given-names></name><name><surname>Strålin</surname><given-names>K</given-names></name><name><surname>Gredmark-Russ</surname><given-names>S</given-names></name><name><surname>Klingström</surname><given-names>J</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name><collab>Karolinska KI/K COVID‐19 Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Innate lymphoid cell composition associates with COVID-19 disease severity</article-title><source>Clinical &amp; Translational Immunology</source><volume>9</volume><elocation-id>e1224</elocation-id><pub-id pub-id-type="doi">10.1002/cti2.1224</pub-id><pub-id pub-id-type="pmid">33343897</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Rovina</surname><given-names>N</given-names></name><name><surname>Akinosoglou</surname><given-names>K</given-names></name><name><surname>Antoniadou</surname><given-names>A</given-names></name><name><surname>Antonakos</surname><given-names>N</given-names></name><name><surname>Damoraki</surname><given-names>G</given-names></name><name><surname>Gkavogianni</surname><given-names>T</given-names></name><name><surname>Adami</surname><given-names>ME</given-names></name><name><surname>Katsaounou</surname><given-names>P</given-names></name><name><surname>Ntaganou</surname><given-names>M</given-names></name><name><surname>Kyriakopoulou</surname><given-names>M</given-names></name><name><surname>Dimopoulos</surname><given-names>G</given-names></name><name><surname>Koutsodimitropoulos</surname><given-names>I</given-names></name><name><surname>Velissaris</surname><given-names>D</given-names></name><name><surname>Koufargyris</surname><given-names>P</given-names></name><name><surname>Karageorgos</surname><given-names>A</given-names></name><name><surname>Katrini</surname><given-names>K</given-names></name><name><surname>Lekakis</surname><given-names>V</given-names></name><name><surname>Lupse</surname><given-names>M</given-names></name><name><surname>Kotsaki</surname><given-names>A</given-names></name><name><surname>Renieris</surname><given-names>G</given-names></name><name><surname>Theodoulou</surname><given-names>D</given-names></name><name><surname>Panou</surname><given-names>V</given-names></name><name><surname>Koukaki</surname><given-names>E</given-names></name><name><surname>Koulouris</surname><given-names>N</given-names></name><name><surname>Gogos</surname><given-names>C</given-names></name><name><surname>Koutsoukou</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure</article-title><source>Cell Host &amp; Microbe</source><volume>27</volume><fpage>992</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.009</pub-id><pub-id pub-id-type="pmid">32320677</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giefing-Kröll</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Lepperdinger</surname><given-names>G</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>How sex and age affect immune responses, susceptibility to infections, and response to vaccination</article-title><source>Aging Cell</source><volume>14</volume><fpage>309</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1111/acel.12326</pub-id><pub-id pub-id-type="pmid">25720438</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title><source>Bioinformatics (Oxford, England)</source><volume>32</volume><fpage>2847</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id><pub-id pub-id-type="pmid">27207943</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>Knight</surname><given-names>SR</given-names></name><name><surname>van Smeden</surname><given-names>M</given-names></name><name><surname>Abubakar</surname><given-names>I</given-names></name><name><surname>Lipman</surname><given-names>M</given-names></name><name><surname>Quartagno</surname><given-names>M</given-names></name><name><surname>Pius</surname><given-names>R</given-names></name><name><surname>Buchan</surname><given-names>I</given-names></name><name><surname>Carson</surname><given-names>G</given-names></name><name><surname>Drake</surname><given-names>TM</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Fairfield</surname><given-names>CJ</given-names></name><name><surname>Gamble</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>CA</given-names></name><name><surname>Halpin</surname><given-names>S</given-names></name><name><surname>Hardwick</surname><given-names>HE</given-names></name><name><surname>Holden</surname><given-names>KA</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Mclean</surname><given-names>KA</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name><name><surname>Norman</surname><given-names>L</given-names></name><name><surname>Olliaro</surname><given-names>PL</given-names></name><name><surname>Pritchard</surname><given-names>MG</given-names></name><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Scott-Brown</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Solomon</surname><given-names>T</given-names></name><name><surname>Sudlow</surname><given-names>C</given-names></name><name><surname>Swann</surname><given-names>OV</given-names></name><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name><collab>ISARIC4C Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study</article-title><source>The Lancet. Respiratory Medicine</source><volume>9</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30559-2</pub-id><pub-id pub-id-type="pmid">33444539</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimshony</surname><given-names>T</given-names></name><name><surname>Senderovich</surname><given-names>N</given-names></name><name><surname>Avital</surname><given-names>G</given-names></name><name><surname>Klochendler</surname><given-names>A</given-names></name><name><surname>de Leeuw</surname><given-names>Y</given-names></name><name><surname>Anavy</surname><given-names>L</given-names></name><name><surname>Gennert</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Dor</surname><given-names>Y</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Yanai</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0938-8</pub-id><pub-id pub-id-type="pmid">27121950</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis</article-title><source>Journal of Medical Virology</source><volume>93</volume><fpage>820</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1002/jmv.26326</pub-id><pub-id pub-id-type="pmid">32691881</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heald-Sargent</surname><given-names>T</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Rippe</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Kociolek</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)</article-title><source>JAMA Pediatrics</source><volume>174</volume><fpage>902</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.3651</pub-id><pub-id pub-id-type="pmid">32745201</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>I</given-names></name><name><surname>Pranata</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis</article-title><source>Journal of Intensive Care</source><volume>8</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/s40560-020-00453-4</pub-id><pub-id pub-id-type="pmid">32483488</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>AM</given-names></name><name><surname>Pasman</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Gamradt</surname><given-names>P</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of tissue protection in lethal respiratory viral-bacterial coinfection</article-title><source>Science (New York, N.Y.)</source><volume>340</volume><fpage>1230</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1126/science.1233632</pub-id><pub-id pub-id-type="pmid">23618765</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhaveri</surname><given-names>KA</given-names></name><name><surname>Trammell</surname><given-names>RA</given-names></name><name><surname>Toth</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effect of environmental temperature on sleep, locomotor activity, core body temperature and immune responses of C57BL/6J mice</article-title><source>Brain, Behavior, and Immunity</source><volume>21</volume><fpage>975</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2007.03.007</pub-id><pub-id pub-id-type="pmid">17467232</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>TC</given-names></name><name><surname>Biele</surname><given-names>G</given-names></name><name><surname>Mühlemann</surname><given-names>B</given-names></name><name><surname>Veith</surname><given-names>T</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Beheim-Schwarzbach</surname><given-names>J</given-names></name><name><surname>Bleicker</surname><given-names>T</given-names></name><name><surname>Tesch</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Menzel</surname><given-names>P</given-names></name><name><surname>Schwarzer</surname><given-names>R</given-names></name><name><surname>Zuchowski</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>J</given-names></name><name><surname>Krumbholz</surname><given-names>A</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Edelmann</surname><given-names>A</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimating infectiousness throughout SARS-CoV-2 infection course</article-title><source>Science (New York, N.Y.)</source><volume>373</volume><elocation-id>eabi5273</elocation-id><pub-id pub-id-type="doi">10.1126/science.abi5273</pub-id><pub-id pub-id-type="pmid">34035154</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>N</given-names></name><name><surname>Kuo</surname><given-names>HH</given-names></name><name><surname>Boucau</surname><given-names>J</given-names></name><name><surname>Farmer</surname><given-names>JR</given-names></name><name><surname>Allard-Chamard</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Piechocka-Trocha</surname><given-names>A</given-names></name><name><surname>Lefteri</surname><given-names>K</given-names></name><name><surname>Osborn</surname><given-names>M</given-names></name><name><surname>Bals</surname><given-names>J</given-names></name><name><surname>Bartsch</surname><given-names>YC</given-names></name><name><surname>Bonheur</surname><given-names>N</given-names></name><name><surname>Caradonna</surname><given-names>TM</given-names></name><name><surname>Chevalier</surname><given-names>J</given-names></name><name><surname>Chowdhury</surname><given-names>F</given-names></name><name><surname>Diefenbach</surname><given-names>TJ</given-names></name><name><surname>Einkauf</surname><given-names>K</given-names></name><name><surname>Fallon</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Finn</surname><given-names>KK</given-names></name><name><surname>Garcia-Broncano</surname><given-names>P</given-names></name><name><surname>Hartana</surname><given-names>CA</given-names></name><name><surname>Hauser</surname><given-names>BM</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Kaplonek</surname><given-names>P</given-names></name><name><surname>Karpell</surname><given-names>M</given-names></name><name><surname>Koscher</surname><given-names>EC</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ly</surname><given-names>NL</given-names></name><name><surname>Michell</surname><given-names>AR</given-names></name><name><surname>Rassadkina</surname><given-names>Y</given-names></name><name><surname>Seiger</surname><given-names>K</given-names></name><name><surname>Sessa</surname><given-names>L</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ticheli</surname><given-names>HJ</given-names></name><name><surname>Waring</surname><given-names>MT</given-names></name><name><surname>Zhu</surname><given-names>AL</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Lichterfeld</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Padera</surname><given-names>RF</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><collab>Massachusetts Consortium on Pathogen Readiness Specimen Working Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.025</pub-id><pub-id pub-id-type="pmid">32877699</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlberg</surname><given-names>J</given-names></name><name><surname>Chong</surname><given-names>DSY</given-names></name><name><surname>Lai</surname><given-names>WYY</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do</article-title><source>American Journal of Epidemiology</source><volume>159</volume><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/aje/kwh056</pub-id><pub-id pub-id-type="pmid">14742282</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kassambara</surname><given-names>A.</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>ggpubr: “ggplot2</source><publisher-name>Based Publication Ready Plots</publisher-name></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Flanagan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex differences in immune responses</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>626</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klose</surname><given-names>CSN</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis</article-title><source>Nature Immunology</source><volume>17</volume><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/ni.3489</pub-id><pub-id pub-id-type="pmid">27328006</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kløverpris</surname><given-names>HN</given-names></name><name><surname>Kazer</surname><given-names>SW</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name><name><surname>Mabuka</surname><given-names>JM</given-names></name><name><surname>Wellmann</surname><given-names>A</given-names></name><name><surname>Ndhlovu</surname><given-names>Z</given-names></name><name><surname>Yadon</surname><given-names>MC</given-names></name><name><surname>Nhamoyebonde</surname><given-names>S</given-names></name><name><surname>Muenchhoff</surname><given-names>M</given-names></name><name><surname>Simoni</surname><given-names>Y</given-names></name><name><surname>Andersson</surname><given-names>F</given-names></name><name><surname>Kuhn</surname><given-names>W</given-names></name><name><surname>Garrett</surname><given-names>N</given-names></name><name><surname>Burgers</surname><given-names>WA</given-names></name><name><surname>Kamya</surname><given-names>P</given-names></name><name><surname>Pretorius</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Moodley</surname><given-names>A</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Kasprowicz</surname><given-names>V</given-names></name><name><surname>Abdool Karim</surname><given-names>SS</given-names></name><name><surname>Goulder</surname><given-names>P</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Ndung’u</surname><given-names>T</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression</article-title><source>Immunity</source><volume>44</volume><fpage>391</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.006</pub-id><pub-id pub-id-type="pmid">26850658</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kompaniyets</surname><given-names>L</given-names></name><name><surname>Goodman</surname><given-names>AB</given-names></name><name><surname>Belay</surname><given-names>B</given-names></name><name><surname>Freedman</surname><given-names>DS</given-names></name><name><surname>Sucosky</surname><given-names>MS</given-names></name><name><surname>Lange</surname><given-names>SJ</given-names></name><name><surname>Gundlapalli</surname><given-names>AV</given-names></name><name><surname>Boehmer</surname><given-names>TK</given-names></name><name><surname>Blanck</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>70</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7010e4</pub-id><pub-id pub-id-type="pmid">33705371</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Rosenfeld</surname><given-names>AM</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><name><surname>Agyekum</surname><given-names>RS</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Kuthuru</surname><given-names>O</given-names></name><name><surname>Apostolidis</surname><given-names>SA</given-names></name><name><surname>Bershaw</surname><given-names>L</given-names></name><name><surname>Dougherty</surname><given-names>J</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Pattekar</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Weirick</surname><given-names>ME</given-names></name><name><surname>Arevalo</surname><given-names>CP</given-names></name><name><surname>Bolton</surname><given-names>MJ</given-names></name><name><surname>Goodwin</surname><given-names>EC</given-names></name><name><surname>Anderson</surname><given-names>EM</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Jones</surname><given-names>TK</given-names></name><name><surname>Mangalmurti</surname><given-names>NS</given-names></name><name><surname>Luning Prak</surname><given-names>ET</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comprehensive mapping of immune perturbations associated with severe COVID-19</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eabd7114</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abd7114</pub-id><pub-id pub-id-type="pmid">32669287</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsova</surname><given-names>A</given-names></name><name><surname>Brockhoff</surname><given-names>PB</given-names></name><name><surname>Christensen</surname><given-names>RHB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>lmerTest package: tests in linear mixed effects models</article-title><source>Journal of Statistical Software</source><volume>82</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.18637/jss.v082.i13</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laxminarayan</surname><given-names>R</given-names></name><name><surname>Wahl</surname><given-names>B</given-names></name><name><surname>Dudala</surname><given-names>SR</given-names></name><name><surname>Gopal</surname><given-names>K</given-names></name><name><surname>Mohan B</surname><given-names>C</given-names></name><name><surname>Neelima</surname><given-names>S</given-names></name><name><surname>Jawahar Reddy</surname><given-names>KS</given-names></name><name><surname>Radhakrishnan</surname><given-names>J</given-names></name><name><surname>Lewnard</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epidemiology and transmission dynamics of COVID-19 in two Indian states</article-title><source>Science (New York, N.Y.)</source><volume>370</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1126/science.abd7672</pub-id><pub-id pub-id-type="pmid">33154136</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Rhee</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Son</surname><given-names>HJ</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Choo</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Loeb</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea</article-title><source>JAMA Internal Medicine</source><volume>180</volume><fpage>1447</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.3862</pub-id><pub-id pub-id-type="pmid">32780793</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Tse</surname><given-names>LV</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Sanders</surname><given-names>W</given-names></name><name><surname>Fritch</surname><given-names>EJ</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Moorman</surname><given-names>NJ</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice</article-title><source>Cell</source><volume>183</volume><fpage>1070</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.050</pub-id><pub-id pub-id-type="pmid">33031744</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>Bhattacharyya</surname><given-names>RP</given-names></name><name><surname>Mina</surname><given-names>MJ</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name><name><surname>Smole</surname><given-names>S</given-names></name><name><surname>Woolley</surname><given-names>A</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comparison of Viral Levels in Individuals with or without Symptoms at Time of COVID-19 Testing among 32,480 Residents and Staff of Nursing Homes and Assisted Living Facilities in Massachusetts</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.20.20157792</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>Bhattacharyya</surname><given-names>RP</given-names></name><name><surname>Mina</surname><given-names>MJ</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name><name><surname>Smole</surname><given-names>S</given-names></name><name><surname>Woolley</surname><given-names>A</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross-sectional assessment of SARS-CoV-2 viral load by symptom status in Massachusetts congregate living facilities</article-title><source>The Journal of Infectious Diseases</source><volume>224</volume><fpage>1658</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab367</pub-id><pub-id pub-id-type="pmid">34255846</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Dewey</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis</article-title><source>Frontiers in Pediatrics</source><volume>8</volume><elocation-id>591132</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2020.591132</pub-id><pub-id pub-id-type="pmid">33224909</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licciardi</surname><given-names>F</given-names></name><name><surname>Pruccoli</surname><given-names>G</given-names></name><name><surname>Denina</surname><given-names>M</given-names></name><name><surname>Parodi</surname><given-names>E</given-names></name><name><surname>Taglietto</surname><given-names>M</given-names></name><name><surname>Rosati</surname><given-names>S</given-names></name><name><surname>Montin</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children</article-title><source>Pediatrics</source><volume>146</volume><elocation-id>e20201711</elocation-id><pub-id pub-id-type="doi">10.1542/peds.2020-1711</pub-id><pub-id pub-id-type="pmid">32439816</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hallmarks of Health</article-title><source>Cell</source><volume>184</volume><fpage>33</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.034</pub-id><pub-id pub-id-type="pmid">33340459</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>LoTempio</surname><given-names>JE</given-names></name><name><surname>Billings</surname><given-names>EA</given-names></name><name><surname>Draper</surname><given-names>K</given-names></name><name><surname>Ralph</surname><given-names>C</given-names></name><name><surname>Moshgriz</surname><given-names>M</given-names></name><name><surname>Duong</surname><given-names>N</given-names></name><name><surname>Bard</surname><given-names>JD</given-names></name><name><surname>Gai</surname><given-names>X</given-names></name><name><surname>Wessel</surname><given-names>D</given-names></name><name><surname>DeBiasi</surname><given-names>RL</given-names></name><name><surname>Campos</surname><given-names>JM</given-names></name><name><surname>Vilain</surname><given-names>E</given-names></name><name><surname>Delaney</surname><given-names>M</given-names></name><name><surname>Michael</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Novel SARS-CoV-2 spike variant identified through viral genome sequencing of the pediatric Washington D.C. COVID-19 outbreak</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2021.02.08.21251344</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>M</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential analysis of count data--the DESeq2 package</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Silva</surname><given-names>RM</given-names></name><name><surname>Pinkerton</surname><given-names>KE</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>GWK</given-names></name><collab>Chinese Pediatric Novel Coronavirus Study Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Infection in Children</article-title><source>The New England Journal of Medicine</source><volume>382</volume><fpage>1663</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2005073</pub-id><pub-id pub-id-type="pmid">32187458</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>TBR</given-names></name><name><surname>Silva</surname><given-names>J</given-names></name><name><surname>Sundaram</surname><given-names>M</given-names></name><name><surname>Ellingson</surname><given-names>MK</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Oh</surname><given-names>JE</given-names></name><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Tokuyama</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Venkataraman</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>A</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wyllie</surname><given-names>AL</given-names></name><name><surname>Vogels</surname><given-names>CBF</given-names></name><name><surname>Earnest</surname><given-names>R</given-names></name><name><surname>Lapidus</surname><given-names>S</given-names></name><name><surname>Ott</surname><given-names>IM</given-names></name><name><surname>Moore</surname><given-names>AJ</given-names></name><name><surname>Muenker</surname><given-names>MC</given-names></name><name><surname>Fournier</surname><given-names>JB</given-names></name><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Odio</surname><given-names>CD</given-names></name><name><surname>Casanovas-Massana</surname><given-names>A</given-names></name><name><surname>Team</surname><given-names>YI</given-names></name><name><surname>Herbst</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>AC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Schulz</surname><given-names>WL</given-names></name><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Dela Cruz</surname><given-names>C</given-names></name><name><surname>Farhadian</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>AI</given-names></name><name><surname>Omer</surname><given-names>SB</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Longitudinal analyses reveal immunological misfiring in severe COVID-19</article-title><source>Nature</source><volume>584</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2588-y</pub-id><pub-id pub-id-type="pmid">32717743</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019</article-title><source>Clinical Infectious Diseases</source><volume>71</volume><fpage>2174</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa641</pub-id><pub-id pub-id-type="pmid">32445579</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Márquez</surname><given-names>EJ</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name><name><surname>Marches</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>RJ</given-names></name><name><surname>Nehar-Belaid</surname><given-names>D</given-names></name><name><surname>Eroglu</surname><given-names>A</given-names></name><name><surname>Mellert</surname><given-names>DJ</given-names></name><name><surname>Kuchel</surname><given-names>GA</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Ucar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sexual-dimorphism in human immune system aging</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>751</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14396-9</pub-id><pub-id pub-id-type="pmid">32029736</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Giles</surname><given-names>JR</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Wu</surname><given-names>JE</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>D’Andrea</surname><given-names>K</given-names></name><name><surname>Manne</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Reilly</surname><given-names>JP</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Kuthuru</surname><given-names>O</given-names></name><name><surname>Dougherty</surname><given-names>J</given-names></name><name><surname>Nzingha</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Pattekar</surname><given-names>A</given-names></name><name><surname>Goodwin</surname><given-names>EC</given-names></name><name><surname>Anderson</surname><given-names>EM</given-names></name><name><surname>Weirick</surname><given-names>ME</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Arevalo</surname><given-names>CP</given-names></name><name><surname>Bolton</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Lacey</surname><given-names>SF</given-names></name><name><surname>Ramage</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Apostolidis</surname><given-names>SA</given-names></name><name><surname>Huang</surname><given-names>AC</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><collab>UPenn COVID Processing Unit</collab><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title><source>Science (New York, N.Y.)</source><volume>369</volume><elocation-id>eabc8511</elocation-id><pub-id pub-id-type="doi">10.1126/science.abc8511</pub-id><pub-id pub-id-type="pmid">32669297</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauvais-Jarvis</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19</article-title><source>Diabetes</source><volume>69</volume><fpage>1857</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.2337/dbi19-0023</pub-id><pub-id pub-id-type="pmid">32669390</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarville</surname><given-names>JL</given-names></name><name><surname>Ayres</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Disease tolerance: concept and mechanisms</article-title><source>Current Opinion in Immunology</source><volume>50</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.12.003</pub-id><pub-id pub-id-type="pmid">29253642</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>DS</given-names></name><name><surname>Soares</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Disease tolerance as a defense strategy</article-title><source>Science (New York, N.Y.)</source><volume>335</volume><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1126/science.1214935</pub-id><pub-id pub-id-type="pmid">22363001</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monticelli</surname><given-names>LA</given-names></name><name><surname>Sonnenberg</surname><given-names>GF</given-names></name><name><surname>Abt</surname><given-names>MC</given-names></name><name><surname>Alenghat</surname><given-names>T</given-names></name><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Doering</surname><given-names>TA</given-names></name><name><surname>Angelosanto</surname><given-names>JM</given-names></name><name><surname>Laidlaw</surname><given-names>BJ</given-names></name><name><surname>Yang</surname><given-names>CY</given-names></name><name><surname>Sathaliyawala</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Diamond</surname><given-names>JM</given-names></name><name><surname>Goldrath</surname><given-names>AW</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name><name><surname>Collman</surname><given-names>RG</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus</article-title><source>Nature Immunology</source><volume>12</volume><fpage>1045</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1031/ni.2131</pub-id><pub-id pub-id-type="pmid">21946417</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monticelli</surname><given-names>LA</given-names></name><name><surname>Osborne</surname><given-names>LC</given-names></name><name><surname>Noti</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>SV</given-names></name><name><surname>Zaiss</surname><given-names>DMW</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions</article-title><source>PNAS</source><volume>112</volume><fpage>10762</fpage><lpage>10767</lpage><pub-id pub-id-type="doi">10.1073/pnas.1509070112</pub-id><pub-id pub-id-type="pmid">26243875</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudd</surname><given-names>PA</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Turner</surname><given-names>JS</given-names></name><name><surname>Souquette</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>D</given-names></name><name><surname>Bender</surname><given-names>D</given-names></name><name><surname>Bosanquet</surname><given-names>JP</given-names></name><name><surname>Anand</surname><given-names>NJ</given-names></name><name><surname>Striker</surname><given-names>DA</given-names></name><name><surname>Martin</surname><given-names>RS</given-names></name><name><surname>Boon</surname><given-names>ACM</given-names></name><name><surname>House</surname><given-names>SL</given-names></name><name><surname>Remy</surname><given-names>KE</given-names></name><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Presti</surname><given-names>RM</given-names></name><name><surname>O’Halloran</surname><given-names>JA</given-names></name><name><surname>Powderly</surname><given-names>WG</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eabe3024</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abe3024</pub-id><pub-id pub-id-type="pmid">33187979</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Driscoll</surname><given-names>M</given-names></name><name><surname>Ribeiro Dos Santos</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cummings</surname><given-names>DAT</given-names></name><name><surname>Azman</surname><given-names>AS</given-names></name><name><surname>Paireau</surname><given-names>J</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name><name><surname>Cauchemez</surname><given-names>S</given-names></name><name><surname>Salje</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Age-specific mortality and immunity patterns of SARS-CoV-2. Nature</article-title><source>Nature</source><volume>590</volume><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2918-0</pub-id><pub-id pub-id-type="pmid">33137809</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patin</surname><given-names>E</given-names></name><name><surname>Hasan</surname><given-names>M</given-names></name><name><surname>Bergstedt</surname><given-names>J</given-names></name><name><surname>Rouilly</surname><given-names>V</given-names></name><name><surname>Libri</surname><given-names>V</given-names></name><name><surname>Urrutia</surname><given-names>A</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Scepanovic</surname><given-names>P</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Jönsson</surname><given-names>F</given-names></name><name><surname>Beitz</surname><given-names>B</given-names></name><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Lim</surname><given-names>YW</given-names></name><name><surname>Hunkapiller</surname><given-names>J</given-names></name><name><surname>Zepeda</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Piasecka</surname><given-names>B</given-names></name><name><surname>Leloup</surname><given-names>C</given-names></name><name><surname>Rogge</surname><given-names>L</given-names></name><name><surname>Huetz</surname><given-names>F</given-names></name><name><surname>Peguillet</surname><given-names>I</given-names></name><name><surname>Lantz</surname><given-names>O</given-names></name><name><surname>Fontes</surname><given-names>M</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Quintana-Murci</surname><given-names>L</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name><collab>Milieu Intérieur Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors</article-title><source>Nature Immunology</source><volume>19</volume><fpage>302</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0049-7</pub-id><pub-id pub-id-type="pmid">29476184</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peckham</surname><given-names>H</given-names></name><name><surname>de Gruijter</surname><given-names>NM</given-names></name><name><surname>Raine</surname><given-names>C</given-names></name><name><surname>Radziszewska</surname><given-names>A</given-names></name><name><surname>Ciurtin</surname><given-names>C</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Rosser</surname><given-names>EC</given-names></name><name><surname>Webb</surname><given-names>K</given-names></name><name><surname>Deakin</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6317</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19741-6</pub-id><pub-id pub-id-type="pmid">33298944</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrilli</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Rajagopalan</surname><given-names>H</given-names></name><name><surname>O’Donnell</surname><given-names>L</given-names></name><name><surname>Chernyak</surname><given-names>Y</given-names></name><name><surname>Tobin</surname><given-names>KA</given-names></name><name><surname>Cerfolio</surname><given-names>RJ</given-names></name><name><surname>Francois</surname><given-names>F</given-names></name><name><surname>Horwitz</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study</article-title><source>BMJ (Clinical Research Ed.)</source><volume>369</volume><elocation-id>m1966</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1966</pub-id><pub-id pub-id-type="pmid">32444366</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piasecka</surname><given-names>B</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Urrutia</surname><given-names>A</given-names></name><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Patin</surname><given-names>E</given-names></name><name><surname>Posseme</surname><given-names>C</given-names></name><name><surname>Bergstedt</surname><given-names>J</given-names></name><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Rouilly</surname><given-names>V</given-names></name><name><surname>MacPherson</surname><given-names>CR</given-names></name><name><surname>Hasan</surname><given-names>M</given-names></name><name><surname>Albaud</surname><given-names>B</given-names></name><name><surname>Gentien</surname><given-names>D</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name><name><surname>Quintana-Murci</surname><given-names>L</given-names></name><name><surname>Consortium</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges</article-title><source>PNAS</source><volume>115</volume><fpage>E488</fpage><lpage>E497</lpage><pub-id pub-id-type="doi">10.1073/pnas.1714765115</pub-id><pub-id pub-id-type="pmid">29282317</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poline</surname><given-names>J</given-names></name><name><surname>Gaschignard</surname><given-names>J</given-names></name><name><surname>Leblanc</surname><given-names>C</given-names></name><name><surname>Madhi</surname><given-names>F</given-names></name><name><surname>Foucaud</surname><given-names>E</given-names></name><name><surname>Nattes</surname><given-names>E</given-names></name><name><surname>Faye</surname><given-names>A</given-names></name><name><surname>Bonacorsi</surname><given-names>S</given-names></name><name><surname>Mariani</surname><given-names>P</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Smati-Lafarge</surname><given-names>M</given-names></name><name><surname>Caseris</surname><given-names>M</given-names></name><name><surname>Basmaci</surname><given-names>R</given-names></name><name><surname>Lachaume</surname><given-names>N</given-names></name><name><surname>Ouldali</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Systematic SARS-CoV-2 screening at hospital admission in children:a French prospective multicenter study</article-title><source>Clinical Infectious Diseases</source><volume>72</volume><fpage>2215</fpage><lpage>2217</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1044</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2020">2020</year><data-title>R: A Language and Environment for Statistical Computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ra</surname><given-names>SH</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>GU</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection</article-title><source>Thorax</source><volume>76</volume><fpage>61</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2020-215042</pub-id><pub-id pub-id-type="pmid">32963115</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Råberg</surname><given-names>L</given-names></name><name><surname>Sim</surname><given-names>D</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Disentangling genetic variation for resistance and tolerance to infectious diseases in animals</article-title><source>Science (New York, N.Y.)</source><volume>318</volume><fpage>812</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1126/science.1148526</pub-id><pub-id pub-id-type="pmid">17975068</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rak</surname><given-names>GD</given-names></name><name><surname>Osborne</surname><given-names>LC</given-names></name><name><surname>Siracusa</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Bayat</surname><given-names>A</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Volk</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing</article-title><source>The Journal of Investigative Dermatology</source><volume>136</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/JID.2015.406</pub-id><pub-id pub-id-type="pmid">26802241</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauber</surname><given-names>S</given-names></name><name><surname>Luber</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Maul</surname><given-names>L</given-names></name><name><surname>Soare</surname><given-names>A</given-names></name><name><surname>Wohlfahrt</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>NY</given-names></name><name><surname>Dietel</surname><given-names>K</given-names></name><name><surname>Bozec</surname><given-names>A</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Kaplan</surname><given-names>MH</given-names></name><name><surname>Weigmann</surname><given-names>B</given-names></name><name><surname>Zaiss</surname><given-names>MM</given-names></name><name><surname>Fearon</surname><given-names>U</given-names></name><name><surname>Veale</surname><given-names>DJ</given-names></name><name><surname>Cañete</surname><given-names>JD</given-names></name><name><surname>Distler</surname><given-names>O</given-names></name><name><surname>Rivellese</surname><given-names>F</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Neurath</surname><given-names>MF</given-names></name><name><surname>McKenzie</surname><given-names>ANJ</given-names></name><name><surname>Wirtz</surname><given-names>S</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Distler</surname><given-names>JHW</given-names></name><name><surname>Ramming</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells</article-title><source>Nature Medicine</source><volume>23</volume><fpage>938</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1038/nm.4373</pub-id><pub-id pub-id-type="pmid">28714991</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>JS</given-names></name><name><surname>Narasimhan</surname><given-names>M</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>McGinn</surname><given-names>T</given-names></name><name><surname>Davidson</surname><given-names>KW</given-names></name><name><surname>Barnaby</surname><given-names>DP</given-names></name><name><surname>Becker</surname><given-names>LB</given-names></name><name><surname>Chelico</surname><given-names>JD</given-names></name><name><surname>Cohen</surname><given-names>SL</given-names></name><name><surname>Cookingham</surname><given-names>J</given-names></name><name><surname>Coppa</surname><given-names>K</given-names></name><name><surname>Diefenbach</surname><given-names>MA</given-names></name><name><surname>Dominello</surname><given-names>AJ</given-names></name><name><surname>Duer-Hefele</surname><given-names>J</given-names></name><name><surname>Falzon</surname><given-names>L</given-names></name><name><surname>Gitlin</surname><given-names>J</given-names></name><name><surname>Hajizadeh</surname><given-names>N</given-names></name><name><surname>Harvin</surname><given-names>TG</given-names></name><name><surname>Hirschwerk</surname><given-names>DA</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Kozel</surname><given-names>ZM</given-names></name><name><surname>Marrast</surname><given-names>LM</given-names></name><name><surname>Mogavero</surname><given-names>JN</given-names></name><name><surname>Osorio</surname><given-names>GA</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Zanos</surname><given-names>TP</given-names></name><collab>the Northwell COVID-19 Research Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area</article-title><source>JAMA</source><volume>323</volume><fpage>2052</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6775</pub-id><pub-id pub-id-type="pmid">32320003</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riphagen</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>X</given-names></name><name><surname>Gonzalez-Martinez</surname><given-names>C</given-names></name><name><surname>Wilkinson</surname><given-names>N</given-names></name><name><surname>Theocharis</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hyperinflammatory shock in children during COVID-19 pandemic</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>1607</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31094-1</pub-id><pub-id pub-id-type="pmid">32386565</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Schieber</surname><given-names>AMP</given-names></name><name><surname>Redford</surname><given-names>SE</given-names></name><name><surname>Shokhirev</surname><given-names>MN</given-names></name><name><surname>Leblanc</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name><name><surname>Ayres</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cooperative Metabolic Adaptations in the Host Can Favor Asymptomatic Infection and Select for Attenuated Virulence in an Enteric Pathogen</article-title><source>Cell</source><volume>175</volume><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.016</pub-id><pub-id pub-id-type="pmid">30100182</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho-Shimizu</surname><given-names>V</given-names></name><name><surname>Brodin</surname><given-names>P</given-names></name><name><surname>Cobat</surname><given-names>A</given-names></name><name><surname>Biggs</surname><given-names>CM</given-names></name><name><surname>Toubiana</surname><given-names>J</given-names></name><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Henrickson</surname><given-names>SE</given-names></name><name><surname>Belot</surname><given-names>A</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><collab>MIS-C@CHGE</collab></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20210446</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20210446</pub-id><pub-id pub-id-type="pmid">33904890</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>DS</given-names></name><name><surname>Ayres</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases</article-title><source>Nature Reviews. Immunology</source><volume>8</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1038/nri2432</pub-id><pub-id pub-id-type="pmid">18927577</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>EP</given-names></name><name><surname>Haverfield</surname><given-names>J</given-names></name><name><surname>Ursin</surname><given-names>RL</given-names></name><name><surname>Tannenbaum</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Considering how biological sex impacts immune responses and COVID-19 outcomes</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0348-8</pub-id><pub-id pub-id-type="pmid">32528136</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solana</surname><given-names>R</given-names></name><name><surname>Tarazona</surname><given-names>R</given-names></name><name><surname>Gayoso</surname><given-names>I</given-names></name><name><surname>Lesur</surname><given-names>O</given-names></name><name><surname>Dupuis</surname><given-names>G</given-names></name><name><surname>Fulop</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans</article-title><source>Seminars in Immunology</source><volume>24</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2012.04.008</pub-id><pub-id pub-id-type="pmid">22560929</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesoriero</surname><given-names>JM</given-names></name><name><surname>Swain</surname><given-names>CAE</given-names></name><name><surname>Pierce</surname><given-names>JL</given-names></name><name><surname>Zamboni</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Holtgrave</surname><given-names>DR</given-names></name><name><surname>Gonzalez</surname><given-names>CJ</given-names></name><name><surname>Udo</surname><given-names>T</given-names></name><name><surname>Morne</surname><given-names>JE</given-names></name><name><surname>Hart-Malloy</surname><given-names>R</given-names></name><name><surname>Rajulu</surname><given-names>DT</given-names></name><name><surname>Leung</surname><given-names>SYJ</given-names></name><name><surname>Rosenberg</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State</article-title><source>JAMA Network Open</source><volume>4</volume><elocation-id>e2037069</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.37069</pub-id><pub-id pub-id-type="pmid">33533933</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdoni</surname><given-names>L</given-names></name><name><surname>Mazza</surname><given-names>A</given-names></name><name><surname>Gervasoni</surname><given-names>A</given-names></name><name><surname>Martelli</surname><given-names>L</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name><name><surname>Ciuffreda</surname><given-names>M</given-names></name><name><surname>Bonanomi</surname><given-names>E</given-names></name><name><surname>D’Antiga</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>1771</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31103-X</pub-id><pub-id pub-id-type="pmid">32410760</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Eberl</surname><given-names>G</given-names></name><name><surname>Koyasu</surname><given-names>S</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>McKenzie</surname><given-names>ANJ</given-names></name><name><surname>Mebius</surname><given-names>RE</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate Lymphoid Cells: 10 Years On</article-title><source>Cell</source><volume>174</volume><fpage>1054</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.017</pub-id><pub-id pub-id-type="pmid">30142344</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Huen</surname><given-names>SC</given-names></name><name><surname>Luan</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Gallezot</surname><given-names>JD</given-names></name><name><surname>Booth</surname><given-names>CJ</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral Inflammation</article-title><source>Cell</source><volume>166</volume><fpage>1512</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.026</pub-id><pub-id pub-id-type="pmid">27610573</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lifshitz</surname><given-names>L</given-names></name><name><surname>Gellatly</surname><given-names>K</given-names></name><name><surname>Vinton</surname><given-names>CL</given-names></name><name><surname>Busman-Sahay</surname><given-names>K</given-names></name><name><surname>McCauley</surname><given-names>S</given-names></name><name><surname>Vangala</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Derr</surname><given-names>A</given-names></name><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Kucukural</surname><given-names>A</given-names></name><name><surname>McDonel</surname><given-names>P</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Greenough</surname><given-names>T</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Somsouk</surname><given-names>M</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells</article-title><source>Nature Immunology</source><volume>21</volume><fpage>274</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0593-9</pub-id><pub-id pub-id-type="pmid">32066947</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>E</given-names></name><name><surname>Bamford</surname><given-names>A</given-names></name><name><surname>Kenny</surname><given-names>J</given-names></name><name><surname>Kaforou</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>CE</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Ramnarayan</surname><given-names>P</given-names></name><name><surname>Fraisse</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>O</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Kucera</surname><given-names>F</given-names></name><name><surname>Brierley</surname><given-names>J</given-names></name><name><surname>McDougall</surname><given-names>M</given-names></name><name><surname>Carter</surname><given-names>M</given-names></name><name><surname>Tremoulet</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>C</given-names></name><name><surname>Herberg</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name><name><surname>Lyall</surname><given-names>H</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><collab>PIMS-TS Study Group and EUCLIDS and PERFORM Consortia</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2</article-title><source>JAMA</source><volume>324</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.10369</pub-id><pub-id pub-id-type="pmid">32511692</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Averick</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>McGowan</surname><given-names>L</given-names></name><name><surname>François</surname><given-names>R</given-names></name><name><surname>Grolemund</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Bache</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Ooms</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Seidel</surname><given-names>D</given-names></name><name><surname>Spinu</surname><given-names>V</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Vaughan</surname><given-names>D</given-names></name><name><surname>Wilke</surname><given-names>C</given-names></name><name><surname>Woo</surname><given-names>K</given-names></name><name><surname>Yutani</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Welcome to the Tidyverse</article-title><source>Journal of Open Source Software</source><volume>4</volume><elocation-id>1686</elocation-id><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieduwilt</surname><given-names>F</given-names></name><name><surname>Lenth</surname><given-names>C</given-names></name><name><surname>Ctistis</surname><given-names>G</given-names></name><name><surname>Plachetka</surname><given-names>U</given-names></name><name><surname>Möller</surname><given-names>M</given-names></name><name><surname>Wackerbarth</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evaluation of an on-site surface enhanced Raman scattering sensor for benzotriazole</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>8260</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-65181-z</pub-id><pub-id pub-id-type="pmid">32427879</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Monticelli</surname><given-names>LA</given-names></name><name><surname>Saenz</surname><given-names>SA</given-names></name><name><surname>Chi</surname><given-names>AWS</given-names></name><name><surname>Sonnenberg</surname><given-names>GF</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>De Obaldia</surname><given-names>ME</given-names></name><name><surname>Bailis</surname><given-names>W</given-names></name><name><surname>Bryson</surname><given-names>JL</given-names></name><name><surname>Toscano</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Haczku</surname><given-names>A</given-names></name><name><surname>Pear</surname><given-names>WS</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Bhandoola</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>T cell factor 1 is required for group 2 innate lymphoid cell generation</article-title><source>Immunity</source><volume>38</volume><fpage>694</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.003</pub-id><pub-id pub-id-type="pmid">23601684</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Saldi</surname><given-names>TK</given-names></name><name><surname>Gonzales</surname><given-names>PK</given-names></name><name><surname>Lasda</surname><given-names>E</given-names></name><name><surname>Decker</surname><given-names>CJ</given-names></name><name><surname>Tat</surname><given-names>KL</given-names></name><name><surname>Fink</surname><given-names>MR</given-names></name><name><surname>Hager</surname><given-names>CR</given-names></name><name><surname>Davis</surname><given-names>JC</given-names></name><name><surname>Ozeroff</surname><given-names>CD</given-names></name><name><surname>Muhlrad</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>SK</given-names></name><name><surname>Fattor</surname><given-names>WT</given-names></name><name><surname>Meyerson</surname><given-names>NR</given-names></name><name><surname>Paige</surname><given-names>CL</given-names></name><name><surname>Gilchrist</surname><given-names>AR</given-names></name><name><surname>Barbachano-Guerrero</surname><given-names>A</given-names></name><name><surname>Worden-Sapper</surname><given-names>ER</given-names></name><name><surname>Wu</surname><given-names>SS</given-names></name><name><surname>Brisson</surname><given-names>GR</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Dowell</surname><given-names>RD</given-names></name><name><surname>Leinwand</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name><name><surname>Sawyer</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Just 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in communities</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2104547118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2104547118</pub-id><pub-id pub-id-type="pmid">33972412</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonker</surname><given-names>LM</given-names></name><name><surname>Neilan</surname><given-names>AM</given-names></name><name><surname>Bartsch</surname><given-names>Y</given-names></name><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Regan</surname><given-names>J</given-names></name><name><surname>Arya</surname><given-names>P</given-names></name><name><surname>Gootkind</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>G</given-names></name><name><surname>Hardcastle</surname><given-names>M</given-names></name><name><surname>St John</surname><given-names>A</given-names></name><name><surname>Appleman</surname><given-names>L</given-names></name><name><surname>Chiu</surname><given-names>ML</given-names></name><name><surname>Fialkowski</surname><given-names>A</given-names></name><name><surname>De la Flor</surname><given-names>D</given-names></name><name><surname>Lima</surname><given-names>R</given-names></name><name><surname>Bordt</surname><given-names>EA</given-names></name><name><surname>Yockey</surname><given-names>LJ</given-names></name><name><surname>D’Avino</surname><given-names>P</given-names></name><name><surname>Fischinger</surname><given-names>S</given-names></name><name><surname>Shui</surname><given-names>JE</given-names></name><name><surname>Lerou</surname><given-names>PH</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Ryan</surname><given-names>ET</given-names></name><name><surname>Bassett</surname><given-names>IV</given-names></name><name><surname>Irimia</surname><given-names>D</given-names></name><name><surname>Edlow</surname><given-names>AG</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses</article-title><source>The Journal of Pediatrics</source><volume>227</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2020.08.037</pub-id><pub-id pub-id-type="pmid">32827525</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonker</surname><given-names>LM</given-names></name><name><surname>Gilboa</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>AF</given-names></name><name><surname>Senussi</surname><given-names>Y</given-names></name><name><surname>Lazarovits</surname><given-names>R</given-names></name><name><surname>Boribong</surname><given-names>BP</given-names></name><name><surname>Bartsch</surname><given-names>YC</given-names></name><name><surname>Loiselle</surname><given-names>M</given-names></name><name><surname>Rivas</surname><given-names>MN</given-names></name><name><surname>Porritt</surname><given-names>RA</given-names></name><name><surname>Lima</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>JP</given-names></name><name><surname>Farkas</surname><given-names>EJ</given-names></name><name><surname>Burns</surname><given-names>MD</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Hajizadeh</surname><given-names>S</given-names></name><name><surname>Lopez</surname><given-names>XIH</given-names></name><name><surname>Kreuzer</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>EE</given-names></name><name><surname>Han</surname><given-names>I</given-names></name><name><surname>Griswold</surname><given-names>K</given-names><suffix>Jr</suffix></name><name><surname>Barry</surname><given-names>NC</given-names></name><name><surname>Thompson</surname><given-names>DB</given-names></name><name><surname>Church</surname><given-names>G</given-names></name><name><surname>Edlow</surname><given-names>AG</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Walt</surname><given-names>DR</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>149633</elocation-id><pub-id pub-id-type="doi">10.1172/JCI149633</pub-id><pub-id pub-id-type="pmid">34032635</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters</article-title><source>OMICS</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yudanin</surname><given-names>NA</given-names></name><name><surname>Schmitz</surname><given-names>F</given-names></name><name><surname>Flamar</surname><given-names>AL</given-names></name><name><surname>Thome</surname><given-names>JJC</given-names></name><name><surname>Tait Wojno</surname><given-names>E</given-names></name><name><surname>Moeller</surname><given-names>JB</given-names></name><name><surname>Schirmer</surname><given-names>M</given-names></name><name><surname>Latorre</surname><given-names>IJ</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name><name><surname>Monticelli</surname><given-names>LA</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity</article-title><source>Immunity</source><volume>50</volume><fpage>505</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.01.012</pub-id><pub-id pub-id-type="pmid">30770247</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yukselen</surname><given-names>O</given-names></name><name><surname>Turkyilmaz</surname><given-names>O</given-names></name><name><surname>Ozturk</surname><given-names>AR</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Kucukural</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DolphinNext: a distributed data processing platform for high throughput genomics</article-title><source>BMC Genomics</source><volume>21</volume><elocation-id>310</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-020-6714-x</pub-id><pub-id pub-id-type="pmid">32306927</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Hou</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>DT</given-names></name><name><surname>Li</surname><given-names>FZ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Laboratory findings of COVID-19: a systematic review and meta-analysis</article-title><source>Scandinavian Journal of Clinical and Laboratory Investigation</source><volume>80</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1080/00365513.2020.1768587</pub-id><pub-id pub-id-type="pmid">32449374</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Meng</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis</article-title><source>International Journal of Infectious Diseases</source><volume>96</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.04.086</pub-id><pub-id pub-id-type="pmid">32376308</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional exhaustion of antiviral lymphocytes in COVID-19 patients</article-title><source>Cellular &amp; Molecular Immunology</source><volume>17</volume><fpage>533</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0402-2</pub-id><pub-id pub-id-type="pmid">32203188</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74681.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>Evangelos J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gnjpq42</institution-id><institution>National and Kapodistrian University of Athens, Medical School</institution></institution-wrap><country>Greece</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.01.14.21249839" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.14.21249839"/></front-stub><body><p>The manuscript shows striking data that circulating innate lymphoid cells (ILCs) decline over human age, more in males than in females, and that a further decline in their prominence is associated with severe COVID-19 in both elderly and paediatric situations. While the findings remain correlative as yet, they shed further light on the complex immune dysregulation of COVID-19, and underline the potential importance of innate lymphoid cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74681.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Giamarellos-Bourboulis</surname><given-names>Evangelos J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gnjpq42</institution-id><institution>National and Kapodistrian University of Athens, Medical School</institution></institution-wrap><country>Greece</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Giamarellos-Bourboulis</surname><given-names>Evangelos J</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gnjpq42</institution-id><institution>National and Kapodistrian University of Athens, Medical School</institution></institution-wrap><country>Greece</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Kyriazopoulou</surname><given-names>Evdoxia</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gnjpq42</institution-id><institution>National and Kapodistrian University of Athens, Medical School</institution></institution-wrap><country>Greece</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.14.21249839">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.01.14.21249839v4">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Evangelos J Giamarellos-Bourboulis as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Evdoxia Kyriazopoulou (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>– The Introduction is too long and it is based on references of the past before the arrival of COVID-19.</p><p>– One main concern is that the authors suggest that depletion of innate lymphoid cells (ILC) is the main driver of the lymphopenia of severe COVID-19. To prove this the authors need to provide the absolute counts of all subpopulations and to provide serial follow-up data. They also need to explain how hypoglobulinemia of patients is explained if depletion involves only ILC. There are at least two publications (PMID 32320677 and 34678611) suggesting defect in antigen presentation and they are not even referenced in this submission.</p><p>– The authors need to provide data on the cytokine production capacity of ILC.</p><p>– The authors should clarify when exactly blood sampling took place (at admission? during hospitalization? Before any treatment start?).</p><p>– According to Table 1 median duration of symptoms is about 20 days which is quiet a long period; normally patients are admitted after the first week. If sampling is not done at admission, administered therapy especially corticosteroids may influence flow cytometry results. If therapy was administered this has to be part of the regression results in Table 3.</p><p>– Another concern is the absence in presentation of comorbidities as they can perhaps also influence results. If these data are unavailable, this is for sure a limitation and should be discussed.</p><p>– In SARS-CoV2 infected adults, as reported widely, infections were highest in young adults, and mortality was highest in the elderly and increased approximately 1 log for each 20 year age group. Linear regression revealed that age, sex, and ILC and NK cell frequency were inversely correlated with hospitalization, and the association between ILC and NK frequency was retained when age and sex were adjusted for. Subsequent multiple logistic regression analysis showed that adjusting for age, sex, and symptom duration, only ILC frequency was significantly associated with an increased risk of hospitalization, the duration of hospital stay, and an increase in CRP. The same association between ILC frequency, but not other lymphocytes, and COVID was observed in an additional paediatric cohort. However, in rare Paediatric cases who developed MIS-C, both ILCs and T cells were significantly reduced. To link blood ILCs to what is happening on the lung, bioinformatic analysis of sequence data generated from sorted blood ILCS in compared to that of published gut and lung ILC datasets. Although, the authors argue this shows blood ILCs are transcriptionally more closely aligned to lung ILCs, the validity of this analysis is hard to judge without more detail and, as the data does not come from COVID subjects, its value in supporting the manuscript is unclear. Finally, ILCs from uninfected males produced less amphiregulin, important in lung homeostasis and repair.</p><p>– The loss of ILCs from circulation has been shown in several diseases, including HIV, TB, and COVID, as has the association between circulating ILCs and age. The strength of this manuscript is in using multiple regression to show that the association between ILC loss and disease severity is retained when age is controlled for, as age is such an important factor in COVID. However, the overall conclusion that elevated circulating ILCs support disease tolerance, while interesting, is not directly supported by any data. For example, a reduction in blood ILCs may indicate the recruitment of these cells to the lung, as has been shown for TB (Ardain et al., Nature 2019). In which case, an increased frequency of blood ILCs may not be protective per se, but just reflective of less lung involvement. Therefore, I suggest the title and abstract be altered to reflect the data presented more directly.</p><p>– The study consistently refers to cell abundance but is actually reporting the frequency of cells. It is an important distinction in this context, as the total lymphocyte count declines with age. Therefore, if there are differences in the rates of decline, it can create the impression of an increase in specific subsets which are actually declining but just at a slower than the median (as may be happening with NK cells for example). To avoid any potential confusion, I suggest the authors present and discuss the data as frequencies of total lymphocytes (or PBMC as appropriate).</p><p>– For the lymphocyte specific analysis, what is lacking is reporting of the other lymphocyte subsets, such as B-cells. It may not be possible to represent these as individual populations, depending on the markers used, but they could be presented as the remainder of the whole. In this way, the reader can get a sense of what is happening in the lymphocyte compartment as a whole. This is important given that absolute values are not available.</p><p>-I am a bit concerned that the synchronization of the paeds sample is too big an issue in this small sample size to give much confidence in the effects observed – the MISC subjects are measured at about 2months and 6-7 months, and the COVID at 6-8 months and one at 11 months. Given this, how much weight do the authors think this analysis carries?</p><p>– The authors compare the RNA read-out of the peripheral ILCs and they use previous arrays from lung ILCs to suggest that they are coming from the lung. This is far too arbitrary since this is a different cohort. Ardain et al., sorted ILC2s and ILC3s from the lung whilst Yudanin sorted ILC1, 2 and 3 from the gut – and I think only sequenced 3 and 1. ILC2 are the dominant population in blood. Is it possible that the greater apparent overlap between the blood and lung relates to the type of ILCs sequenced rather than the biological overlap between these compartments?. More generally, does this analysis add useful information to the current study? Analysis of the transcriptional activity of ILCs during COVID may have provided evidence of their role in disease tolerance, as hypothesised by the authors. However, as the PBMC sequenced were uninfected healthy controls, this is impossible.</p><p>– Figure 2.B – it might be informative to plot males and females separately in each age bin. We know there is an equal ratio of males and females but we don’t know if this is equally distributed by age. From Figure 3 it looks like there may be a bias toward younger female and older male controls? Presenting it this way will make it easy for the reader to assess.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74681.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions (for the authors):</p><p>– The Introduction is too long and it is based on references of the past before the arrival of COVID-19.</p></disp-quote><p>To address these points, the Introduction was edited to start with a brief but more general statement about the features of severe COVID-19 (page 3, lines 89-92) and to include the two references suggested in comment #2 (PMID 32320677 and 34678611). Several sentences on innate lymphoid cells were deleted to focus the Introduction on COVID-19.</p><disp-quote content-type="editor-comment"><p>– One main concern is that the authors suggest that depletion of innate lymphoid cells (ILC) is the main driver of the lymphopenia of severe COVID-19. To prove this the authors need to provide the absolute counts of all subpopulations and to provide serial follow-up data. They also need to explain how hypoglobulinemia of patients is explained if depletion involves only ILC. There are at least two publications (PMID 32320677 and 34678611) suggesting defect in antigen presentation and they are not even referenced in this submission.</p></disp-quote><p>We thank the reviewers for the chance to clarify these points.</p><p>– It was not our intention to suggest that ILC defects are the primary cause of immune abnormalities such as lymphopenia or the defects in antigen presentation that the reviewer mentioned. As we wrote (page 6, lines 157-161), “The goal of this study was to determine whether the abundance of any blood lymphoid cell population was altered in COVID-19, independent of age, sex, and global lymphopenia, and whether abundance of any lymphoid cell population correlated with clinical outcome in SARS-CoV-2 infection.” After taking into account the effects of age and sex, our main finding was that reduction in ILC number was significantly associated with COVID-19 severity, risk and duration of hospitalization, and with increase in blood inflammatory markers such as CRP.</p><p>– To clarify this point we modified our abstract to say that our study “suggests” that lower ILC abundance, “contributes” to increased COVID-19 severity with age and in males (page 2, line 76).</p><p>– As stated above in response to point #1, we have expanded our introduction about the abnormalities associated with severe COVID-19 and have incorporated the two suggested references (page 3, lines 89-92).</p><disp-quote content-type="editor-comment"><p>– The authors need to provide data on the cytokine production capacity of ILC.</p></disp-quote><p>In response to this comment we have added a new panel showing that, in addition to being decreased in abundance, blood ILCs in people hospitalized for COVID-19 have significantly decreased capacity to produce amphiregulin (Figure 6D). The text of the abstract (page 2, line 69-71), results (page 44, lines 676-681), discussion (page 49, lines 786-788), and figure legends (page 46, line 703-706), have been modified accordingly.</p><disp-quote content-type="editor-comment"><p>– The authors should clarify when exactly blood sampling took place (at admission? During hospitalization? Before any treatment start?).</p></disp-quote><p>We now mention that samples from hospitalized patients were collected during admission (page 12, lines 165-168). In addition, we now mention that the COVID-19 blood samples were collected during the first wave of COVID-19, between March 31 and June 3<sup>rd</sup>, 2020 (page 12, lines 165-166); this time was before corticosteroids were demonstrated to be efficacious for severe COVID-19. Records of treatment interventions other than intubation were not available to us for these patients and this point has been added to the text (page 17, lines 271-272).</p><disp-quote content-type="editor-comment"><p>– According to Table 1 median duration of symptoms is about 20 days which is quiet a long period; normally patients are admitted after the first week. If sampling is not done at admission, administered therapy especially corticosteroids may influence flow cytometry results. If therapy was administered this has to be part of the regression results in Table 3.</p></disp-quote><p>We agree that timing of corticosteroids would be an important variable to include in Table 3. As discussed in response to point #4, this information was not available, and could not be included in the analysis. That being said, as indicated in the text (page 30, lines 457-463) and in the footnote to Table 3 (page 30), we included symptom duration at the time of sample collection as a covariate in the regression analysis presented in Table 3.</p><disp-quote content-type="editor-comment"><p>– Another concern is the absence in presentation of comorbidities as they can perhaps also influence results. If these data are unavailable, this is for sure a limitation and should be discussed.</p></disp-quote><p>In response to this suggestion we obtained information about diabetes mellitus. These data are now listed in Table 1 (page 18), mentioned in the text (page 17, lines 276-278), and included in the calculations for the odds of hospitalization presented Table 3 (page 30) and discussed on page 30 (lines 457-463). Accounting for diabetes mellitus diagnosis had minimal effect on the statistical results.</p><disp-quote content-type="editor-comment"><p>– In SARS-CoV2 infected adults, as reported widely, infections were highest in young adults, and mortality was highest in the elderly and increased approximately 1 log for each 20 year age group. Linear regression revealed that age, sex, and ILC and NK cell frequency were inversely correlated with hospitalization, and the association between ILC and NK frequency was retained when age and sex were adjusted for. Subsequent multiple logistic regression analysis showed that adjusting for age, sex, and symptom duration, only ILC frequency was significantly associated with an increased risk of hospitalization, the duration of hospital stay, and an increase in CRP. The same association between ILC frequency, but not other lymphocytes, and COVID was observed in an additional paediatric cohort. However, in rare Paediatric cases who developed MIS-C, both ILCs and T cells were significantly reduced. To link blood ILCs to what is happening on the lung, bioinformatic analysis of sequence data generated from sorted blood ILCS in compared to that of published gut and lung ILC datasets. Although, the authors argue this shows blood ILCs are transcriptionally more closely aligned to lung ILCs, the validity of this analysis is hard to judge without more detail and, as the data does not come from COVID subjects, its value in supporting the manuscript is unclear. Finally, ILCs from uninfected males produced less amphiregulin, important in lung homeostasis and repair.</p></disp-quote><p>We thank the reviewer for the extensive summary of our findings. The comment they make here is addressed in point #12 below.</p><disp-quote content-type="editor-comment"><p>– The loss of ILCs from circulation has been shown in several diseases, including HIV, TB, and COVID, as has the association between circulating ILCs and age. The strength of this manuscript is in using multiple regression to show that the association between ILC loss and disease severity is retained when age is controlled for, as age is such an important factor in COVID. However, the overall conclusion that elevated circulating ILCs support disease tolerance, while interesting, is not directly supported by any data. For example, a reduction in blood ILCs may indicate the recruitment of these cells to the lung, as has been shown for TB (Ardain et al., Nature 2019). In which case, an increased frequency of blood ILCs may not be protective per se, but just reflective of less lung involvement. Therefore, I suggest the title and abstract be altered to reflect the data presented more directly.</p></disp-quote><p>In response to this comment we have added new data and changed the text as recommended:</p><p>– The term “disease tolerance” has been removed from the title (page 1, line 3).</p><p>– The abstract now mentions that blood ILCs from people hospitalized with COVID-19 have significantly decreased capacity to produce amphiregulin (page 2, lines 69-71). See point number 3 above regarding new Figure 6D.</p><p>– The possibility that ILCs are sequestered in the lung is now mentioned in the text (page 40, lines 614-615).</p><disp-quote content-type="editor-comment"><p>– The study consistently refers to cell abundance but is actually reporting the frequency of cells. It is an important distinction in this context, as the total lymphocyte count declines with age. Therefore, if there are differences in the rates of decline, it can create the impression of an increase in specific subsets which are actually declining but just at a slower than the median (as may be happening with NK cells for example). To avoid any potential confusion, I suggest the authors present and discuss the data as frequencies of total lymphocytes (or PBMC as appropriate).</p></disp-quote><p>As suggested by the reviewer, the majority of the data are reported as ILCs per million lymphocytes. This is stated in the text and figure legends, and indicated in the Y axis labels on the figures. As the reviewer also points out, certain analyses were per million PBMCs; critical findings such as the effect of COVID-19 on ILCs were essentially the same per million lymphocytes or PBMCs (page 27, lines 418-420; Supplementary file 2e). The same was true for the other lymphoid cell subsets, including the significant increase in NK cells with age that was referred to by the reviewer.</p><disp-quote content-type="editor-comment"><p>– For the lymphocyte specific analysis, what is lacking is reporting of the other lymphocyte subsets, such as B-cells. It may not be possible to represent these as individual populations, depending on the markers used, but they could be presented as the remainder of the whole. In this way, the reader can get a sense of what is happening in the lymphocyte compartment as a whole. This is important given that absolute values are not available.</p></disp-quote><p>The reviewer makes an important point. To provide a sense of the lymphocyte compartment as a whole, we had analyzed lymphocyte abundance as a fraction of total PBMCs. This was described in the text on page 25, line 379-384,</p><p>“the effect of COVID-19 on total lymphocyte abundance was addressed with multiple linear regression. After accounting for effects of age and sex, individuals hospitalized with severe COVID-19 had 1.33-fold (95%CI: 1.49–1.19; p = 1.22 x 10<sup>-6</sup>) fewer total lymphocytes among PBMCs than did controls (Supplementary file 2d)”.</p><disp-quote content-type="editor-comment"><p>-I am a bit concerned that the synchronization of the paeds sample is too big an issue in this small sample size to give much confidence in the effects observed – the MISC subjects are measured at about 2months and 6-7 months, and the COVID at 6-8 months and one at 11 months. Given this, how much weight do the authors think this analysis carries?</p></disp-quote><p>We thank the reviewer for raising this question regarding the difference in timing of follow-up blood collections for the MISC-C subjects vs the COVID-19 subjects in Figure 4E (page 38). If the results had been different, the difference in timing would have been a problem. But, given the directionality of the effect we observed, this difference in timing highlights the divergence in rate of recovery of ILC numbers between these two groups: ILC abundance rebounded by 2 months of follow-up for the MIS-C patients, whereas ILC abundance had still not rebounded after 9 months of follow-up for the COVID-19 patients. We now emphasize this point in the text (page 36, lines 570-572).</p><disp-quote content-type="editor-comment"><p>– The authors compare the RNA read-out of the peripheral ILCs and they use previous arrays from lung ILCs to suggest that they are coming from the lung. This is far too arbitrary since this is a different cohort. Ardain et al., sorted ILC2s and ILC3s from the lung whilst Yudanin sorted ILC1, 2 and 3 from the gut – and I think only sequenced 3 and 1. ILC2 are the dominant population in blood. Is it possible that the greater apparent overlap between the blood and lung relates to the type of ILCs sequenced rather than the biological overlap between these compartments?. More generally, does this analysis add useful information to the current study? Analysis of the transcriptional activity of ILCs during COVID may have provided evidence of their role in disease tolerance, as hypothesised by the authors. However, as the PBMC sequenced were uninfected healthy controls, this is impossible.</p></disp-quote><p>Several changes were made to the manuscript in response to these comments:</p><p>– We agree that it would have been better if we had presented RNA-Seq data on lung ILCs from people hospitalized with COVID-19. The text now states that our attempts to profile ILCs from COVID-19 lung samples were unsuccessful (page 40, lines 610-612). In our previous work concerning intestinal ILCs from people living with HIV-1, biopsies had to be processed fresh within the hour (Nat Immunol 21:274); we were unable to profile intestinal ILCs from frozen or fixed tissues and suspect a similar issue holds for the viability of lung ILCs in COVID-19.</p><p>– We also agree that it would have been better if we had RNA-Seq data for ILCs isolated from the blood of people hospitalized with COVID-19. This was not possible because the limited sample available was prioritized for the FACS experiments. These samples had low numbers of ILCs which increased the difficulty of sorting viable cells from this population that is already rare in the blood of uninfected people.</p><p>– Given the significant reductions in blood ILCs in our study, and our inability to profile these rare cells from people with severe COVID, we felt it was important to provide some additional characterization of blood ILCs, even if only from uninfected individuals. Our analysis of global gene expression in blood ILCs from 9 donors shows close similarity to the expression profile of ILCs from the lung. While the reviewer is correct that this is driven in part by the ILC2 character of these cells, many of the 355 genes that distinguish blood and lung ILCs from ILCs of other tissues are not obvious ILC2 genes and could indicate other biologically relevant features in common between blood and lung ILCs (Figure 5B and C, page 42).</p><p>– The transcriptional analysis guided our phenotypic analysis of the blood ILCs (Figure 6 page 45), and, in the revised manuscript, we now show that blood ILCs in people hospitalized for COVID-19 have significantly decreased capacity to produce amphiregulin (Figure 6D). The text of the abstract (page 2, line 69-71), results (page 44, lines 676-681), discussion (page 49, lines 786-788), and figure legends (page 46, line 703-706), have been modified accordingly.</p><disp-quote content-type="editor-comment"><p>– Figure 2.B – it might be informative to plot males and females separately in each age bin. We know there is an equal ratio of males and females but we don't know if this is equally distributed by age. From Figure 3 it looks like there may be a bias toward younger female and older male controls? Presenting it this way will make it easy for the reader to assess.</p></disp-quote><p>To address the reviewer’s question about our control group we compared the male/female ratio for each age group against each of the other age groups in Figure 2. There were no significant differences in this ratio among any of the groups. A table showing this analysis has been added to the supplement (Supplementary file 2c).</p></body></sub-article></article>